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Introduction and Scope of thesis10
Chapter 1
INTRODUCTION
1.1 B-cell non-Hodgkin lymphoma
In the World Health Organization (WHO) tumors of hematopoietic and lymphoid tissues 
are classified according to their cell type of origin, histology, immunophenotype, clinical 
characteristics and genetic aberrations. B-cell non-Hodgkin lymphomas (lymphoma (NHL) 
are  derived  from  mature  B-cells  and  account  for  approximately  70-90%  of  lymphoid 
neoplasms worldwide and 4% of all new cancers each year 1, 2. The median age at diagnosis 
is between 60 and 70 years with a slight male predominance 3. The most common types of 
NHL are diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) which together 
make up more than 60% of all cases 2, 4. Classification of B-cell NHL is predominantly based 
on the hypothesis that different B-cell lymphomas reflect the various stages in normal B-cell 
differentiation, providing a sound biological basis for their classification. This biological 
basis has been expanded with insights into the underlying molecular mechanisms of B-cell 
lymphoma development. Chromosomal aberrations and in particular translocations have 
been shown to be of quintessential importance to lymphomagenesis. For example 90% of 
FL are characterized by the t(14;18)(q32;q21) translocation and subsequent overexpression 
of the anti-apoptotic BCL2 gene located at the chromosome 18q21 breakpoint 5, 6.  
1.2 Diffuse large B-cell lymphoma
DLBCL is characterized by a diffuse proliferation of large lymphoid cells with 3 common 
(centroblastic, immunoblastic and anaplastic) but also many other minor morphological 
variants.  It is defined as a neoplasm of large B-cells with nuclear size equal to or exceeding 
normal macrophage nuclei or more than twice the size of a normal lymphocyte. According 
to  the  Kiel  classification  which  was  one  of  the  major  foundation  stones  of  the  WHO 
classification, they were thought to be derived from blasts in the germinal center B-cell 
reaction (centroblasts) or extra-follicular, late or post germinal center blasts (immunoblasts, 
i.e.  precursors  of  plasma  cells).  Based  on  (dis)similarities  with  normal  B-cells,  a  large 
variety  of  cytomorphological  variants  have  been  described,  including  the  multilobated 
and  anaplastic  variants.  Later  on,  clinical  features  including  the  site  of  presentation 
became more important, resulting in the description of and more clinical and more clinic-
pathologic pathological variants of DLBCL were described.  This evolution has led to a very 
heterogeneous rest group of DLBCL. In the newest WHO classification (2008), DLBCL are 
divided into various specified DLBCL subtypes and DLBCL not otherwise specified (NOS). 
Apart from the primary mediastinal large B cell lymphoma and more rare types such as Introduction and Scope of thesis
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intravascular large B cell lymphoma, which previously were also considered as subtypes of 
DLBCL. The specified subtypes of DLBCL include T cell/histiocyte rich large B cell lymphoma 
(THRLBCL), primary DLBCL of the CNS (PCNSL), testis DLBCL, primary leg type cutaneous 
DLBCL, leg type (PCLBCL) and EBV positive DLBCL of the elderly. 
Clinical aspects
DLBCL accounts for 25% to 30% of all non-Hodgkin lymphoma (NHL) in adults. All specific 
subtypes such as PCNSL, THRLBCL and PCLBCL are relatively rare.  In consequence all DLBCL 
not belonging to these subgroups make up the vast majority of cases. DLBCL that do not 
meet any subgroup defining criteria fall in to the biologically heterogeneous category of 
DLBCL NOS. The median age of DLBCL NOS is between the 6th and 7th decade and there is a 
slight male predominance 7, 8. DLBCL most commonly presents as a de novo malignancy but 
can also present upon progression or transformation of a less aggressive lymphoma such as 
FL, small lymphocytic lymphoma (CLL), and marginal zone B cell lymphoma. DLBCL presents 
either nodal or at virtually any extranodal site with the most common extranodal site being 
gastrointestinal  14. In 40% of patients, presentation is initially only in extranodal sites. In 
general, DLBCL is an aggressive, rapidly growing tumor. Fifty percent of patients present 
with either stage I or II disease. Bone marrow involvement is seen in 11-27% of patients. The 
International Prognostic Index (IPI) categorizes patients into risk groups using unfavorable 
prognostic factors such as age above 60 years, poor performance status, Ann Arbor stage 
II-IV, extranodal involvement in more than two sites, and high serum LDH levels 9.  Although 
DLBCL is an aggressive lymphoma, it is potentially curable. Since the 1970s, standard therapy 
has consisted of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP)  10. 
With the addition of the CD20 monoclonal antibody rituximab (R-CHOP) overall survival 
rates have dramatically improved. The 5 year survival, which for this disease more or less 
reflects the cure rate, varies between 30% and 80% depending on IP status and biological 
heterogeneity 11-13.
Immunophenotype and Genetics
The tumor cells usually express pan B-cell markers such as CD19, CD20, CD22 and CD79a 
although in some cases one or more of these markers may not be expressed  15, 16. CD5, 
usually a marker of T cells, is co-expressed in 5-10% of de novo DLBCL 17. Gene expression 
profiling  has  identified  two  major  prognostically  different  subgroups  of  DLBCL.  The 
expression patterns were related to normal counterparts in B-cell development and were 
characteristic of germinal center B (GCB) cells and (in vitro) activated peripheral B-cells 
(ABC) 18. According to the original publication and most subsequent papers, ABC type DLBCL 12
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had a worse prognosis than GCB type 18. Later on, an immunohistochemical algorithm using 
a combination of CD10, BCL6 and IRF4/MUM1 has been reported to allow classification 
DLBCL  into  GCB-DLBCL  and  non-GCB-DLBCL  (also  called  ABC-DLBCL)  19. Not all studies 
have confirmed the efficacy of this so called Hans algorithm and various other algorithms 
have been proposed 20-22. Also after the introduction of R-CHOP, although controversial, 
ABC-DLBCL still appears to have a poorer prognosis than GCB-DLBCL 23. DLBCL at immune 
privileged sites (which mostly are EBV negative), usually have an activated peripheral B-cell 
type gene expression pattern 24, 25.
The most common translocation in DLBCL involves 3q27 affecting the BCL6 gene 
and occurs in 20-40% of DLBCL  26. BCL2 translocations occur in 20-30% of cases. MYC 
rearrangements are seen in approximately 10% of DLBCL cases 27-30. GCB-DLBCL and non-GCB-
DLBCL differ in the prevalence of specific chromosomal aberrations. For instance, the t(14;18)
(q32;q21) translocation and gains of 12q12 are strongly associated with GCB-DLBCL  31-33.   
Characteristic chromosomal aberrations in non-GCB-DLBCL include trisomy 3, gain of 3q 
and 18q21-q22, loss of 6q21-22 and deletion of the INK4A-ARF locus on chromosome 9 34, 35. 
Ongoing somatic mutations of the immunoglobulin gene somatic (hyper)mutations (SHM), 
which are caused by activity of Activation Induced Deaminase (AID or AICDA), have been 
related to these molecular subtypes of DLBCL. Interestingly, while the total amount of SHM 
is higher in ABC type DLBCL, ongoing SHM are only observed in GCB-DLBCL but are absent 
in ABC-DLBCL 36. This likely reflects the AID activity in GCB type DLBCL and the post GCB 
status of non-GCB-DLBCL. Aberrant SHM somatic hypermutations in PIM1, MYC, RHoH/TTF 
and PAX5, which are also molecular targets of AID, are observed in 50% of all DLBCL 37. Non-
GCB-DLBCL show overexpression of many genes of the NF-κB pathway 38, 39. Also, BLIMP1 is 
a regulator of plasma cell differentiation 40 and has been suggested to function as a tumor 
suppressor in the pathogenesis of non-GCB-DLBCL, in fact 25% of non-GCB-DLBCL show 
inactivating mutations of BLIMP1 41.
1.3 Burkitt lymphoma
BL is first described in 1958 by Denis P Burkitt 42. It is an extremely fast growing lymphoma 
composed of monomorphic medium sized cells with a diffuse monotonous growth pattern 
and numerous macrophages that ingest apoptotic tumor cells resulting in a characteristic 
starry sky pattern. From a biological and pathological point of view, and in contrast to 
DLBCL, BL is a very homogeneous disorder, dominated by a MYC driven, extremely rapid 
proliferation of germinal center derived blasts. Introduction and Scope of thesis
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Clinical aspects
Three clinical variants are recognized; endemic, sporadic and immunodeficiency-associated 
BL. Each of these three variants varies in clinical presentation, morphology and biology. All BL 
are potentially curable diseases. Treatment consists of intensive combination chemotherapy 
regimens with 2 year survival rates of 60-80% with advanced stage disease and up to 100% 
for patients with low stage disease 43-45. In particular in children, poor prognostic factors 
include bone marrow and central nervous system involvement, unresected tumor that is 
larger than 10 cm in diameter and high LDH serum levels 46. 
Endemic BL occurs primarily in equatorial Africa and in Papua New Guinea and 
represents the most common childhood malignancy in these regions with a peak incidence 
of 1:10,000, an average age of 4 to 7 years and a male:female ratio of 2:1 47, 48. Most cases 
are characterized by a latency type I Epstein-Barr virus (EBV) infection, i.e a type in which 
very few viral proteins are expressed by the tumor cells.  Endemic BL usually presents as 
a extranodal mass in the jaw or other facial bones, but also in the abdomen or breasts. 
Only occasionally does it localize to the bone marrow 48, 49. Sporadic BL has no geographical 
predilection and it has an incidence of 1-2% of all lymphomas. It is mainly seen in children 
with a peak between 5-10 years and in young adults with a median age of 30 years. Sporadic 
BL represents 30-50% of all childhood lymphomas and has a male: female ratio of 2 or 3:1 50. 
The presentation of sporadic BL is predominantly abdominal with the ileocaecal region as 
the most frequent site of involvement. Other common sites of involvement are the kidneys, 
breasts and ovaries 47. EBV is detected in 30% of sporadic BL cases.  The immunodeficiency-
associated BL most commonly occurs in patients with human immunodeficiency virus (HIV) 
and BL may be the initially presenting symptom. Incidence rates vary between 2:1,000 in 
children and 1:1,000 in adults and EBV is associated with up to 40% of immunodeficiency 
related BL cases.
Morphology and Immunophenotype
Two  morphological  variants  are  recognized  in  the  WHO  2008,  the  common  type  and 
variant with plasmacytoid differentiation. The most common type shows features of very 
actively proliferating centroblasts within the dark zone of germinal centers. These cells 
have  round  nuclei  with  multiple  small  nucleoli  and  a  very  basophilic  cytoplasm.  Also 
immunophenotypically they share features with centroblasts as they show strong expression 
of surface immunoglobulin IgM, CD20, CD10, CD38, CD77, TCL1 and BCL6, absence or very 
weak expression of CD44,  MUM1/IRF4 and BCL2 protein51. Also terminal deoxynucleotidyl 
transferase (TdT) should be absent. The generation / doubling time of these cells is around 
24 hrs and the Ki-67 proliferation index in BL typically approaches 100% 52. 14
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The rare BL with plasmacytoid differentiation often shows eccentric basophilic 
cytoplasm with a single central nucleolus. Using immunohistochemistry, it has a similar 
phenotype except for the expression of cytoplasmic IgM. This variant has a strong tendency 
to present in immunodeficient patients. 
Pathogenesis
MYC translocations and the resulting overexpression of MYC is considered to be a hallmark 
of  BL.  The  most  common  translocation  is  t(8;14)(q24;q32)  in  which  the  MYC gene is 
translocated to the Ig heavy chain region. Other less common MYC translocations involve 
the lambda or kappa light chain loci on 22q11 and 2p12, respectively. MYC translocations 
are thought to result from class-switch recombination (CSR) and somatic hypermutation 
(SHM), two processes that involve double-strand DNA breaks and mediated by amongst 
other AID 53, 54. Although being a hallmark of BL, MYC translocations are not restricted to BL 
and approximately 10% of the BL cases lack a detectable MYC translocation by fluorescence 
in situ hybridization (FISH) 55.
MYC translocation result in distinct overexpression of the gene. Most interestingly, 
while all Burkitt lymphomas have a very high MYC expression, the normal counterparts, i.e. 
the also rapidly dividing normal germinal center B cells, generally have only very low levels 
of expression (Dominguez-Sola D, Victora GD, Ying CY, Phan RT, Saito M, Nussenzweig MC,
Dalla-Favera R). The proto-oncogene MYC is required for selection in the germinal 
center  and  cyclic  reentry.  Nat  Immunol.  2012  Nov;13(11):1083-91).  The  effect  of  MYC 
overexpression on expression of other genes is a matter of continuous debate. Whereas 
previous papers claimed an cell type specific effect on gene expression of many genes, 
the effect being different for B cells than for other cells, recent reports suggest that MYC 
functions as a non-specific amplifier of gene expression of those genes that are actually 
actively transcribed 129, 130. 
1.4 miRNAs
MicroRNAs (miRNAs) are endogenous small RNAs (21-23 nucleotides) that have emerged 
as key factors in the posttranscriptional control of as many as one third of all protein coding 
genes 56. MiRNAs are located in introns and exons of protein coding genes, in non-protein 
coding genes or in intergenic regions 57. Currently approximately 16,000 miRNAs have been 
identified in different species by cloning and sequence analysis of small RNAs. Of these 
16,000 miRNAs roughly 1,700 are found in humans (miRBase release 19; August 2012).Introduction and Scope of thesis
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Biogenesis and function
Biogenesis of miRNAs generally starts in the nucleus by transcription of primary transcripts 
(pri-miRNAs) by RNA polymerase II (RPII). Pri-miRNAs are processed by Drosha (nuclear 
RNase III) to form hairpin structures of about 70 nucleotides in the nucleus (pre-miRNAs).   
The resulting pre-miRNAs are transported to the cytoplasm by Exportin5 and processed 
by Dicer (RNAse type III) into double stranded duplexes of about 22 nucleotides. A single 
mature strand is generated by unwinding of the duplexes by Helicase. This mature strand 
is incorporated into the RNA induced silencing complex (RISC) and this complex binds to 
its target mRNAs  58-60. Individual miRNA levels in each cell are strictly regulated by the 
transcription machinery, methylation status and also by regulation of its biogenesis 61.
The first miRNAs identified in animals, lin-4 and let-7, were shown to have crucial roles in 
developmental timing in C. elegans 127, 128. Mice deficient for Dicer 1 die around 7.5 days of 
gestation, indicating the importance of miRNAs and other Dicer regulated pathways during 
embryogenesis 62. 
Numerous cellular processes are under regulatory control of miRNAs, including 
proliferation, differentiation, apoptosis and cell cycle kinetics 63. MiRNAs contain a highly 
conserved ”seed” sequence including nucleotide 2 to 7 at the 5’ end 64. This seed sequence 
directs pairing to its specific target mRNAs and results in translational repression and/or 
degradation of the target mRNA dependent of the degree of homology 65-67. It is currently 
thought that the RNA induced silencing complex (RISC) acts in mammals mainly by inhibition 
of translation, and to a lesser extent by degradation of the target gene transcripts. Both 
mechanisms ultimately lead to down regulation of the target protein. An important question 
is whether a specific miRNA has one main target gene in a specific cell type or whether each 
miRNA has many target genes that might be related to the same cellular pathway. Examples 
of both can be found in the current literature 68-70. Another recently reported novel mode of 
miRNA functioning is facilitating intercellular communication by secreting specific miRNAs 
into micro-vesicles or exosomes and delivery of these vesicles to other neighboring cells 71.
Deregulation of miRNAs is directly implicated in the development of cancer and 
many  other  diseases,  including  diabetes,  cardiac  diseases  and  autoimmune  disorders. 
Several tumor suppressor and oncogenic miRNAs have already been identified 72-74. 
1.5 Role of miRNAs in B-cell non-Hodgkin lymphoma
Specific miRNA profiles that characterize different B-cell lymphoma subtypes have been 
reported  75-82.  Several of these miRNAs have been identified by expression analysis in 
lymphomas,  others  by  their  presence  in  genomic  regions  that  were  previously  known 
to  be  commonly  deleted  or  amplified,  but  for  which  no  bona  fide  tumor  suppressor 16
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genes or oncogenes could be identified.  One of the first oncogenic miRNAs identified 
in  B-cell  lymphoma  is  miR-155.  MiR-155  is  highly  expressed  in  germinal  center  B-cell-
derived lymphomas  83-85. Further evidence for an oncogenic role for miR-155 came from 
a study demonstrating that E(mu) miR-155 transgenic mice develop polyclonal pre-B-cell 
proliferations leading to B-cell malignancies at later stages 86. Myeloproliferative disorders 
were  induced  by  overexpression  of  miR-155  in  hematopoietic  stem  cells  in  a  mouse   
model 87. 
A second well known oncogenic miRNA cluster is C13ORF25 also known as the pri-
miR-17~92 cluster. The pri-miRNA contains 6 stemloops with 6 dominant miRNAs i.e. miR-
17, miR-18a, miR-19b, miR-20a, miR-19b and miR-92. An additional miR-17-3p is transcribed 
from the 3’ end of the stem loop containing miR-17. MiR-17~92 is located in the 13q31 region, 
which is often amplified in B-cell lymphoma 88, 89. Overexpression of this cluster in the E(mu) 
MYC mouse B-cell lymphoma model results in accelerated B-cell lymphoma development 90. 
More recently miR-19a and miR-19b have been identified as the key oncogenic components 
necessary  and  sufficient  for  promoting  MYC  induced  lymphomagenesis  by  repressing 
apoptosis 91, 92. Several individual members of this miRNA cluster play an important role in 
proliferation, tumor angiogenesis and suppression of apoptosis 93-96. 
In  addition  to  these  oncogenic  miRNAs,  there  are  also  studies  showing  the 
importance of miRNAs with that display tumor suppressor activities in B-cell lymphoma. 
In CLL, deletion of the 13q14 region targets the primary miRNA transcript of miR-15 and 
miR-16, resulting in down regulation of these miRNAs in the majority of CLL cases 75 and 
increased levels of the anti-apoptotic protein BCL2 97. Deletion of the miR-15 and miR-16 
region in mice causes clonal and autonomously growing indolent B cell lymphoproliferative 
disorders consistent with the spectrum of CLL observed in humans 98.
MiRNAs in DLBCL
MiRNA profiling has revealed a distinct miRNA expression pattern in DLBCL which is different 
from other NHL such as BL, CLL and FL 99, 100. Several studies reported that miRNA signatures 
can segregate DLBCL cases and cell lines into GCB-DLBCL and ABC-DLBCL subgroups 100-107. 
However, only a very limited degree of overlap is seen between the various miRNA predictor 
sets in the different studies. One miRNA profiling study defined three subgroups based on 
MYC target gene levels and this clustering was unrelated to GCB-DLBCL and ABC-DLBCL 
classifications 108. This may be explained by the fact that MYC regulates expression of a large 
number (approximately 60) of miRNAs 87, 109-113. The majority of MYC regulated miRNAs are 
repressed by MYC, but several miRNAs are induced such as the miR-17~92 cluster87, 108, 112. Introduction and Scope of thesis
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The  involvement  of  several  miRNAs  in  DLBCL  was  inferred  from  chromosomal 
regions with recurrent gains or losses not explained by the presence of oncogenes or tumor 
suppressor genes. The genomic region including the polycistron miR-17~92 is amplified in 
12,5% of GCB-DLBLC 88 but not in non-GCB-DLBCL 114. Other recurrent numerical genomic 
aberrations in DLBCL include loci for up to 63 miRNAs including some highly expressed 
miRNAs such as let-7f, miR-15a/16-1, miR-188, miR-222, miR-223, miR-374, miR-424 and 
miR-513 108. 
Several miRNAs have been linked to DLBCL lymphomagenesis. The oncogenic miR-
155 has been shown to be significantly over expressed in DLBCL 73 and more specifically 
in ABC-DLBCL115. MiR-155 directly targets bone morphogenetic protein (BMP)-responsive 
transcriptional factor SMAD5 and overexpression of miR-155 leads to resistance to growth-
inhibitory effects of both TGF-β1 and BMPs in DLBCL116. Another interesting role for miR-155 
in DLBCL is related to both the NF-κB and the Janus kinase JNK pathways. Both pathways 
are constitutively active in non-GCB-DLBCL 115, 117. In DLBCLs that lack inactivating mutations 
of BLIMP1 epigenetic downregulation of BLIMP1 expression may be caused by let-7b which 
targets BLIMP1 and is overexpressed in DLBCL relative to normal GCB-cells 118.
MiRNAs  such  as  miR-18a,  miR-21,  miR-155,  miR-181  and  miR-222  have  been 
shown to be independent predictors of outcome in patients with DLBCL treated with (R-)
CHOP. However, little overlap exists between the various studies with the exception of miR-
155 and miR-21 105, 106, 119, 120. These disappointing results may be partially explained by the 
extreme heterogeneity of DLBCL, both at the pathologic, molecular and clinical level, as well 
by the heterogeneous treatment. 
MiRNAs in Burkitt lymphoma
The MYC oncogene may be considered as the driving gene in the pathogenesis of BL. MYC 
has been shown to enhance expression of the miR-17~92 cluster in BL cases and cell lines 
121, 122. Yet, the relationship between MYC and miR-17~92 is not a one way street. Two 
members of the miR-17~92 cluster; miR-17-5p and miR-20a have been show to target E2F1 
which in turn regulates MYC and vice versa 87. MiR-34b and miR-9* are downregulated 
in MYC translocation negative (but high MYC expressing) BL. MiR-34b targets MYC and 
miR-9* targets E2F1 and as such, both miRNAs may play a role in the regulation of MYC 
overexpression in such exceptional cases of BL 123. The complexity of this regulatory network 
is possibly increased by let-7a that also targets MYC and has been shown to revert MYC 
induced growth in BL cell lines 124. BL shows a distinct miRNA profile that clearly defines it 
from DLBCL 100. Another important miRNA in BL pathogenesis is miR-155. In contrast to its 
normal counterpart, the germinal center B-cell, Burkitt lymphoma lack miR-155 expression 85. 18
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This downregulation is thought to result in high expression of its target activation-induced 
cytidine deaminase (AID). AID is required for immunoglobulin gene diversification in B 
lymphocytes and for double strand breaks. Low miR-155 and high AID might thus possibly 
result in a higher risk of MYC translocation 3,4Introduction and Scope of thesis
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Scope of the thesis
MiRNA expression patterns are deregulated in most cancers. The aim of this thesis is to 
investigate the expression profiles of miRNAs in various subsets of B-cell NHL. As miRNA 
expression levels are influenced by the transcription factor MYC, we also focused on the 
effect of MYC regulated miRNAs in BL.
It is unclear what role the site of presentation plays in the expression of miRNAs 
in DLBCL. In chapter 2, we examined the expression of miRNAs known to be involved in 
lymphomagenesis and determined if these miRNAs show site specific expression in DLBCL. 
We in particular focused, with a specific focus on DLBCL that present at immune privileged 
sites (IP-DLBC), i.e. the central nervous system (CNS) and testis. 
In chapter 3, we describe our results on the processing of the miR-17~92 cluster, 
which is involved in many B cell lymphomas. We analyzed and correlated the levels of 
C13ORF25 and the six members of the miR-17~92 cluster in normal B-cell subsets, 117 NHL 
cases and in 21 NHL cell lines. We studied the induction of the six members of miR-17~92 by 
comparing their expression levels to those of their normal B-cell counterparts. 
To determine the miRNA profile of B-cell NHL we examined in chapter 4 the miRNA 
expression patterns in mantle cell lymphoma, follicular lymphoma, chronic lymphocytic 
leukemia /lymphoma, and Burkitt lymphoma.  We specifically examined the role of MYC on 
the miRNA expression signature of BL. In chapter 5, we studied the role of miRNAs influenced 
by MYC in BL. We selected differentially expressed MYC regulated miRNAs and examine 
their effect in a BL cell line. In chapter 6, we summarize and discuss results presented in this 
thesis and discuss possible future perspectives.20
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Abstract
Recent studies have shown that certain non-coding short RNAs, called miRNAs, play an 
important role in diffuse large B-cell lymphomas. Patients with diffuse large B-cell lymphoma 
have great diversity in both clinical characteristics, site of presentation and outcome. The aim 
of our study is to validate the differential expression in germinal center and non-germinal 
center diffuse large B-cell lymphomas and to study to the extent to which the primary site 
of differentiation is associated with the miRNA expression profile. We studied 50 de novo 
diffuse large B-cell lymphoma for the expression of 15 miRNAs (miR-15a, miR-15b, miR-16, 
miR-17-3p, miR-17-5p, miR-18a, miR-19a, miR-19b, miR-20a, miR-21, miR-92, miR-127, miR-
155, miR-181a and miR-221). Apart from 19 nodal cases without extranodal dissemination 
(stages I and II), we selected three extranodal groups with unambiguous stage I and II disease; 
9 cases of primary central nervous system, 11 cases of primary testicular and 11 cases of 
other primary extranodal diffuse large B-cell lymphomas. All cases were analyzed with 
qRT-PCR. In situ hybridization for the most differentially expressed miRNAs was performed 
to show miRNA expression in tumor cells, but not in background cells. MiR-21 and miR-
19b showed the highest expression levels. No significant differences were seen between 
germinal center and activate B-cell center diffuse large B-cell lymphomas in either the total 
or the nodal group for any of the 15 miRNAs. Two miRNAs showed significant differences 
in expression levels for diffuse large B-cell lymphoma subgroups according to the site of 
presentation. MiR-17-5p showed a significant higher expression level in the central nervous 
system compared with testicular and nodal diffuse large B-cell lymphomas (P<0.05). MiR-
127 levels were significantly higher in testicular than in central nervous system and in nodal 
diffuse large B-cell lymphomas (P<0.05). We conclude that the location of diffuse large B-cell 
lymphoma is an important factor in determining the differential miRNA expression pattern .Specific expression of miR-17-5p and miR-127 in testicular and central nervous system 
diffuse large B-cell lymphoma
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Introduction
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 40% of all adult non-
Hodgkin  lymphomas.  DLBCL  is  a  clinically  heterogeneous  group  of  lymphomas,  which 
presents at different anatomical sites, either nodal or extranodal. Anatomical sites, such 
as the testis and central nervous system, show marked differences in genetic aberrations, 
morphology and clinical behavior 1, 2 . Testicular DLBCL and central nervous system DLBCL both 
have a different biological and clinical behavior compared with other nodal and extranodal 
DLBCLs. Gene expression profiling of untreated de novo DLBCL has revealed three distinct 
subgroups. The first with the characteristics of normal germinal center B cells, the second 
with the characteristics of activated blood memory B-cells and a third group to which no 
profile could be assigned. The germinal center subgroup has a significantly better prognosis 
than the other two non-germinal center subgroups 3, 4, 5 . The introduction of rituximab to 
the standard treatment of patients with DLBCL revealed an increase in complete-response 
rate and overall survival 6 . More recent studies indicate that the addition of rituximab has 
improved the progression-free and overall survival rate, specifically for activated B-cell type 
DLBCL 7, 8 , thus blurring the prognostic differences between DLBCL of germinal center and 
of activated B-cell origin. 
Recently, a group of 21–23 nucleotide long microRNAs (miRNAs) was discovered. 
These  miRNAs  post-transcriptionally  downregulate  protein  expression  on  the  basis  of 
limited sequence complementarity to the 3’-UTR of mRNA transcripts  9 . Many of these 
miRNAs are involved in cancer by targeting oncogenes or tumor suppressor genes 10, 11, 12, 13 . 
Certain miRNAs are reported to play a role in B-cell malignancies and in B-cell development; 
for example, miR-181a overexpression induces a higher percentage B-lineage cells in both 
tissue culture assays and adult mice cells  12, 14, 15, 16, 17 . One of the first miRNAs linked to 
DLBCL was miR-155, which is derived from a longer pri-miR-155, also referred to as BIC. 
Both BIC and miR-155 have a higher expression level in activated DLBCL when compared 
with that in germinal center DLBCL 14, 18, 19, 20, 21 . A putative oncogenic role for this miRNA was 
supported by the spontaneous development of a polyclonal preleukemic B-cell proliferation 
in an Eμ-miR-155 transgenic mice model 22 . Two other miRNAs, miR-21 and 221, have also 
been reported to be expressed at higher levels in non-germinal center DLBCL cell lines and 
cases 21 . Both of these miRNAs target the antiapoptotic BCL2 gene. MiR-15a and miR-16-
1 also target BCL2, and miR-16-1 downregulates cell growth and cell cycle progression 19 . 
These two miRNAs are the most likely targets of the characteristic 13q14 deletion in CLL, 
and are downregulated in 75% of CLL cases 14, 19, 20 . BCL6 is a target of miR-127, and this 
gene has been reported to be downregulated after demethylation of the promoter region 36
Chapter 2
and concurrent higher expression of miR-127. In DLBCL, amplification of 13q31 is associated 
with the overexpression of the pri-miRNA transcript, C13ORF25, containing seven miRNAs, 
miR-18a, miR-19a, miR-19b, miR-20a, miR-17-3p, miR-17-5p and miR-92 23, 24, 25 .
Our goal was to determine whether possible differences in expression levels of 
miRNAs are related to the differences between germinal and non-germinal center DLBCLs, 
or to the primary site of presentation and biological origin of these lymphomas. To that 
end, we selected two groups of distinct extranodal DLBCL cases localized in the testis and 
central nervous system, and compared these groups with other primary extranodal and 
nodal lymphomas.
Materials and Methods
Patients and materials
Forty-one cases of primary Ann Arbor stage I and II nodal and extranodal DLBCLs were 
obtained  from  the  tissue  bank  at  the  Department  of  Pathology  and  Medical  Biology, 
University Medical Center Groningen, Groningen and 10 cases from the Department of 
Pathology, The Netherlands Cancer Institute, Amsterdam. Each case was reviewed by a 
pathologist and a hematologist. Formalin-fixed paraffin-embedded tissue sections were 
stained with hematoxylin and eosin (HE) to determine the percentage of tumor cells. Blocks 
with a tumor cell percentage of 80% or more were used for RNA isolation. All protocols for 
obtaining and studying human tissues and cells were approved by the institution’s review 
board for human subject research.
Tissue microarray (TMA)
For immunohistochemistry, a TMA was generated with three 0.6-mm cores per case inserted 
in a grid pattern into a recipient paraffin block using an MT1 manual tissue arrayer (Beecher 
Instruments, Sun Prairie, USA). Sections were cut (5 μm) and immunohistochemical staining 
was performed with mouse antihuman monoclonal antibodies against CD10 (1:20, 56C6, 
Novacastra, Newcastle, UK), MUM1 (1:25, MUM1p, DAKO, Copenhagen, Denmark) and 
BCL6 (1:20, PG-BP, DAKO) after antigen retrieval. Positive staining was visualized using a 
peroxidase-labeled second step and staining with diaminobenzidine (DAB). DLBCL cases 
were  classified  as  germinal  center  B-cell-like  (germinal  center)  or  non-germinal  center 
B-cell-like (non-germinal center) according to the algorithm as described by Hans et al 3 . A 
uniform cutoff level of 30% was chosen for CD10, BCL6 and MUM1.Specific expression of miR-17-5p and miR-127 in testicular and central nervous system 
diffuse large B-cell lymphoma
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RNA in situ hybridization (RNA ISH)
RNA in situ hybridization was performed as described earlier  18, 26 . miRNA staining was 
performed using an LNA probe antisense to miR-17-5p and miR-127-3p (Exiqon, Denmark) 
in three central nervous system DLBCL cases and in three testicular DLBCL cases, according 
to the manufacturer’s protocol.
RNA isolation 
RNA isolation was performed using the protocol as described by Specht et al 27 . DNAse 
treatment was performed using a Turbo DNA free kit (Ambion, Woodward, USA) according 
to the manufacturer’s instructions. Efficiency of the DNase procedure was checked using a 
multiplex PCR with 5 primer sets specific for different genomic DNA loci, and subsequent 
analysis on a 1.5% agarose gel. No PCR products were seen confirming the effectiveness 
of the DNAse treatment. RNA concentrations were determined on a NanoDrop® ND-1000 
Spectrophotometer (Nano Drop Technologies, Wilmington, Delaware, USA).
qRT-PCR of mature miRNAs and primary miRNA transcripts 
MiRNA reverse transcription of 5ng total RNA was performed using Taqman MicroRNA 
Reverse Transcription Kit and miRNA specific primers in accordance to the instructions 
supplied by the manufacturer (Applied Biosystems, USA). Superscript II (Invitrogen, USA) 
and random hexamer primers were used for reverse transcription of C13ORF25 and BIC 
and U6 using 200ng of total RNA. Quantification was performed using Taqman MicroRNA 
and Taqman Gene Expression Assays together with the 7900HT ABI Fast Real-Time PCR 
system (Applied Biosystems, USA). SYBR green was used for the relative quantification of 
the pri-miRNA C13ORF25. All procedures were in accordance to instructions supplied by the 
manufacturers. PCR reactions were performed in triplicate, positive and negative controls 
were included in each run with an input of 0.44ng for miRNAs and 2ng for the other genes. 
Fluorescence was quantified with the sequence detection system software SDS (version 
2.1, Applied Biosystems, USA). Mean cycle threshold values and standard deviations (SD) 
were calculated for all miRNAs and genes. U6 was selected from several other validated 
housekeeping genes (GAPDH, RP2, HPRT, TBP and B2M) as it showed a uniform expression 
level in all samples and a sufficiently low threshold Ct value (median; 22, SD; 1.7).  Cases with 
a Ct value for U6 > 30 were excluded from further analysis. The amount of target miRNA was 
normalized relative to the amount of U6 (ΔCt = ΔCtmiRNA- ΔCtU6). Relative expression levels 
were expressed as 2-ΔCt. 38
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Data analysis
To determine significant differences between testicular, CNS, nodal and extranodal non-
IP DLBCL a Kruskal-Wallis test was performed with a Dunn’s Multiple Comparison Test 
and a p-value <0.05 was considered significant (GraphPad Prism software, version 3.02). 
To determine significant differences between germinal and non-germinal center DLBCLs 
for a specific miRNA, a two-tailed Mann–Whitney U-test was used, and a P-value <0.05 
was considered significant (SPSS, version 14). Univariate analysis was performed with a 
Pearson’s χ2-test for gender, stage and localization (SPSS, version 14), and a Student’s t-test 
was used to compare age between germinal and non-germinal centers. A P-value <0.05 was 
considered to be significant (GraphPad Prism software, version 3.02).
Results 
All cases were stained for BCL6, CD10 and MUM1 and classified as germinal or non-germinal 
centers according to the algorithm described earlier by Hans et al.3 Results for each case are 
given in Supplementary Table 2. In total, 32% of the cases were positive for BCL6, 26% for 
CD10 and 52% for MUM1. The nodal DLBCL group contained eight germinal and 11 non-
germinal center cases. Eight central nervous system DLBCL cases were classified as non-
germinal and one as germinal center DLBCL. For the testicular DLBCL cases, ten cases were 
classified as non-germinal and one as germinal center. The eleven other extranodal cases 
were classified as germinal center in four cases and non-germinal center in seven cases. 
Comparison of the germinal center with the non-germinal center DLBCL groups using a 
univariate analysis for age, gender, Ann Arbor stage and localization revealed no significant 
differences (Table 1).
In the total DLBCL group, the expression levels of the individual miRNAs varied 
greatly (Figure 1). The most abundant miRNA, miR-21, showed a 100-fold higher expression 
level (median: 28), and miR-19b (median: 8.9) showed a 10-fold higher expression level 
than did miR-15a, miR-15b, miR-17-3p, miR-17-5p, miR-18a, miR-19a, miR-20a, miR-92a, 
miR-127, miR-155, miR-181a and miR-221. MiR-16 showed the lowest level of expression in 
comparison with the other miRNAs (median: 0.01; Table 2). Within the germinal and non-
germinal center groups, miR-21 showed the highest median expression level, 0,25 and 0,34, 
respectively (Table 2).Specific expression of miR-17-5p and miR-127 in testicular and central nervous system 
diffuse large B-cell lymphoma
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Figure 1. Expression levels of all 15 miRNAs. The median (CI= 95%) expression levels of the 15 selected 
miRNAs show that miR-21 has a 100 fold higher expression level and miR-19b has a 10 fold higher 
expression level compared to the other 13 miRNAs.
Tabel 1. Overview of  50 DLBCL cases
Total GCB non-GCB p-value*
n=50 % n=14 % n=36 %
Age 0.39
Median 59 55 60
Range 18-87 27-81 18-87
Gender 0.91
Male 31 63 9 64 20 56%
Female 19 37 6 36 15 44%
Stage 0.33
I 35 71 8 53 28 72%
II 15 29 6 47 8 28%
Localisation 0.15
Extranodal 31 63 6 47 25 69
Nodal 19 37 8 53 11 31%
* Gender, stage and localization were tested using a χ2 test, age localization were tested using a 
student-t test.
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Tabel 2. Median expression levels of all 15 miRNAs in DLBCL subgroups
  All cases GCB non-GCB
Nodal 
DLBCL
Testicular 
DLBCL CNS DLBCL
Extranodal 
non-IP
  n=50 n=15 n=35 n=19 n=11 n=9 n=11
miR-21 0.284 0.251 0.343 0.270 0.270 0.366 0.465
miR-19b 0.089 0.096 0.087 0.094 0.097 0.086 0.073
miR-15b 0.012 0.012 0.012 0.011 0.009 0.016 0.014
miR-92a 0.010 0.009 0.011 0.008 0.022 0.013 0.010
miR-20a 0.009 0.010 0.009 0.012 0.010 0.008 0.006
miR-15a 0.009 0.009 0.009 0.009 0.015 0.009 0.010
miR-19a 0.008 0.010 0.008 0.008 0.011 0.010 0.008
miR-17-5p 0.008 0.007 0.009 0.006 0.010 0.016 0.006
miR-181a 0.006 0.007 0.006 0.006 0.007 0.005 0.005
miR-155 0.003 0.002 0.003 0.003 0.003 0.006 0.001
miR-18a 0.003 0.003 0.003 0.002 0.003 0.005 0.003
miR-221 0.002 0.002 0.002 0.002 0.001 0.003 0.002
miR-17-3p 0.001 0.001 0.001 0.001 0.001 0.001 0.001
miR-127 0.000 0.000 0.000 0.000 0.001 0.000 0.000
miR-16 0.000 0.000 0.000 0.000 0.000 0.000 0.000
The comparison of all 50 cases showed no significant differences between germinal 
and non-germinal center DLBCLs for any of the 15 miRNAs. A second analysis was performed 
using only the nodal group of DLBCL containing eight germinal and eleven non-germinal 
center cases, which again revealed no significant differences between the expression levels 
of the 15 miRNAs (Figure 2).
A separate analysis was made of the specific anatomical sites of presentation 
in testicular, central nervous system, nodal and other extranodal DLBCL cases. MiR-17-
5p  showed  a  significantly  higher  expression  level  in  central  nervous  system  DLBCLs  in 
comparison with that in nodal and testicular DLBCLs (P=0.04; Figure 3A). MiR-127 showed a 
significantly higher expression level in testicular DLBCL in comparison with that in nodal and 
central nervous system DLBCLs (P<0.05; Figure 3B). All other miRNAs showed no significant 
differences in these four DLBCL subgroups.
We subsequently tested the cellular localization of the differentially expressed 
miRNAs using in situ hybridization to confirm that the differential expression was related 
to  higher  expression  levels  in  DLBCL  cells.  RNA-ISH  of  miR-17-5p  in  all  three  central 
nervous system DLBCL cases (Figure 3c), and that of miR-127 in all three testicular DLBCL 
cases (Figure 3d) showed an almost restricted staining of tumor cells. Tumor cells showed 
cytoplasmic and nucleolar staining. MiR-127 has only one proven target, ie, BCL6. Correlation Specific expression of miR-17-5p and miR-127 in testicular and central nervous system 
diffuse large B-cell lymphoma
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 ﾠ Nodal       All cases 
Figure 2.  Similar expression levels of miR-155, miR-21 and miR-221 in nodal germinal and non-
germinal center diffuse large B-cell lymphomas. The expression levels of miR-155 (a), miR-21 (b) and 
miR-221 (c) in nodal and in all 50 diffuse large B-cell lymphoma cases; the line indicates the median 
level. No significant differences are seen between the germinal and non-germinal center groups for 
any of the three miRNAs either only for the nodal cases or for the total group of diffuse large B-cell 
lymphoma cases.42
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Figure 3. Significant differences in the expression levels for miR-17-5p and miR-127. (A) MiR-17-5p 
shows a significant difference in median expression levels between the diffuse large B-cell lymphoma 
groups, with the highest expression in central nervous system diffuse large B-cell lymphoma. (B) 
MiR-127 shows a higher expression level, specifically for testicular diffuse large B-cell lymphoma (* 
p< 0.05). (C) In situ hybridization for miR-17-5p shows cytoplasmic and nucleolar staining not only 
in tumor cells of central nervous system diffuse large B-cell lymphoma but also in cells that do not 
stain for miR-17-5p. (D) The in situ hybridization for miR-127 also shows specific cytoplasmatic and 
nucleolar staining in tumor cells of testicular diffuse large B-cell lymphoma, but not in the Sertoli cells. 
(E) A negative DLBCL case that showed no detectable staining for miR-17-5p. (F) A negative DLBCL case 
that showed no detectable staining for miR-127. 
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between expression levels of miR-127 and expression levels of BCL6 using qRT-PCR (2−ΔC
t) 
was significant (P=0.027) with an inverse Spearman’s coefficient (r=−0.3) in the total DLBCL 
group (data not shown). We also compared the expression levels of miR-127 with the 
immunohistochemistry results for BCL6 protein expression. When the cases were divided 
into two groups on the basis of positive BCL6 staining (n=15) and negative BCL6 staining 
(n=25), expression levels of miR-127 were lower in the BCL6-positive (median level of 0.004) 
compared with that in BCL6-negative group (median: 0.07; P=0.054) (Figure 4). 
Figure 4. Significant differences in the expression levels of miR-127 in BCL protein expression. MiR-
127 shows a significant different expression level (P=0.054) between DLBCL with positive IHC staining 
for BCL6 and DLBCL with negative staining for BCL6.
Discussion
DLBCL is a lymphoma with a widely varying biological and clinical behavior and the different 
anatomical sites in which the presence of primary DLBCL reflects these heterogeneous 
aspects.  Earlier  miRNA  studies  in  DLBCL  usually  comprised  of  a  heterogeneous  group 
containing cases with mixed sites of presentation. To determine the expression of B-cell-
related miRNAs in DLBCL and to examine the differences in miRNA levels in the germinal 
and non-germinal centers of different subgroups of DLBCL and the relation to the site of 
presentation, we examined well-defined groups of primary nodal and extranodal DLBCLs. 
To that end, we selected only Ann Arbor stage I and II cases with nodal, central nervous 
system or testicular presentation, as well as a heterogeneous group of primary extranodal 
DLBCL, also only stage I or II. We used paraffin-embedded tissue for our analysis to allow the 
inclusion of a larger number of cases compared with that in frozen samples. On the basis of 
recent publications, it is evident that miRNA expression studies result in comparable results 
for both paraffin and frozen specimens 21, 28. 
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Consistent with the literature, we found that the testicular DLBCL and central 
nervous system DLBCL were predominantly non-germinal center 29, 30. The distribution in 
the nodal and the heterogeneous other extranodal DLBCL groups was also consistent with 
earlier reports 2, 4. Remarkably, no significant differences in expression levels for any of the 
15 B-cell related miRNAs were found between the germinal and non-germinal center cases 
in our total group of DLBCL. In earlier reports, miR-155, miR-21 and miR-221 levels were 
shown to be higher in non-germinal center DLBCL18, 20, 21. A possible explanation for these 
differences might be that we used specific localizations, ie, primary nodal, testicular, central 
nervous system and a group of heterogeneous extranodal DLBCL. Earlier reports have used 
groups of DLBCL with mixed locations and varying Ann Arbor stages. Eis et al 20 compared a 
heterogeneous group with respect to presentation and stage containing only four germinal 
center and nineteen activated DLBCLs. Kluiver et al 18 investigated a group of eighteen DLBCLs 
from which eleven were extranodal, presenting at eight different anatomical sites. Lawrie et 
al 21 used a heterogeneous group of 35 de novo DLBCLs from which 23 cases presented with 
stage III or IV disease, making a distinction between primary nodal and extranodal almost 
impossible. Lack of differential expression of these three miRNAs between germinal and 
non-germinal center DLBCLs in our study cannot be attributed to the inclusion of central 
nervous system and testicular cases, as analysis of the stage I and II nodal groups and the 
primary stage I and II heterogeneous extranodal groups also showed no differences for miR-
155, miR-21 and miR-221, or for the other 12 miRNAs. This suggests that the differences 
observed in earlier studies and the lack of differential expression in our stage I and II DLBCL 
cases may be related to the inclusion of heterogeneous DLBCL cases.
Using qRT-PCR, we found two highly expressed miRNAs, miR-21 and miR-19b, in 
the DLBCL group. The most abundant, miR-21, showed levels that were 10-fold higher than 
that in miR-19b and 100-fold higher than that in any of the other 13 miRNAs. Our data are 
consistent with Lawrie et al 21 who also showed high miR-21 levels in DLBCL. Interestingly, 
miR-21 has been shown to be highly expressed in a variety of different tumors and is 
associated with the downregulation of BCL2 31 and PTEN 32. MiR-19b also showed a high 
expression with a 10-fold higher expression level than the other 13 miRNAs. MiR-19b is one 
of the seven miRNAs in the polycistron, C13ORF25. C13ORF25 is overexpressed in 70% of 
DLBCLs with 13q31-q32 amplification. Although the miR-17-92 has two homologous clusters, 
the miR-106a-92 cluster on chromosome X and the miR-106b-25 cluster on chromosome 7, 
it is the amplification of the 13q31 locus that has been linked to the overexpression of miR-
17-92 24, 33.
MiR-17-5p,  another  member  of  the  C13ORF25  polycistron,  was  differentially 
expressed  between  the  subgroups  of  DLBCL,  showing  a  significantly  higher  expression Specific expression of miR-17-5p and miR-127 in testicular and central nervous system 
diffuse large B-cell lymphoma
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level in central nervous system DLBCL. C13ORF25 was recently shown to be upregulated by 
binding of MYC to its promoter region 34. Mice models have shown that the overexpression 
of miR-17-92 reduces apoptosis, and further studies have shown that miR-17-5p and miR-
20 target the proapoptotic E2F1 gene 35. Differences in the levels of miR-19b and miR-17-5p 
when compared with those in the five other miRNAs of the C13ORF25 cluster may indicate 
variation  in  processing  efficiency  or  stability  between  the  nodal,  testicular  and  central 
nervous system DLBCL subgroups. Interestingly, central nervous system DLBCL has been 
shown to have a higher expression of MYC than the nodal DLBCL 36. In central nervous system 
DLBCL, only the miR-17-5p and miR-20a cluster members were expressed at a significantly 
higher level, especially in comparison with that in the nodal group. This indicates that both 
MYC and differences in processing and stability of the mature miRNAs of C13ORF25 may 
contribute to the higher expression levels of 17-5p in central nervous system DLBCL.
In the testicular DLBCL, miR-127 levels were significantly higher compared with 
that in the nodal and central nervous system DLBCLs. Earlier studies have shown that 
the  expression  of  miR-127  was  upregulated  after  treatment  with  chromatin-modifying 
drugs,  and  this  induced  the  downregulation  of  the  proto-oncogene  BCL6.  Transfection 
of miR-127, precursors in Ramos cells, designed to mimic endogenous miR-127 caused 
the downregulation of BCL6 protein  10. We showed a negative correlation between the 
expression of BCL6 and the expression for miR-127 in DLBCL, which supports the earlier 
finding that BCL6 is a target for miR-127. BCL6 transcription factor is expressed in germinal 
centers and is associated with germinal center events 37. It is one of the major transcriptional 
regulators of centroblasts and inhibits the differentiation of GC B-cells into plasma and 
memory cells  38. In germinal center DLBCL, low miR-127 levels can result in high BCL6 
expression levels, and thereby keep the tumor cells in the GC developmental stage, giving a 
proliferative advantage. The high level of miR-127 in testicular DLBCL can therefore induce 
the downregulation of BCL6, which is consistent with the non-germinal center phenotype 
of testicular DLBCL.
Differential expression of specific miRNAs in testicular and central nervous system 
lymphomas could also be caused by expression in preexistent non-malignant cells, such as 
Sertoli cells or astrocytes, which might be present in the tumor tissues. We have excluded 
this possibility by selecting cases with >80% tumor cells and by the application of in situ 
hybridization for the two relevant miRNAs, which revealed a selective expression in tumor 
cells. Besides cytoplasmic staining, we also observed nucleolar staining. This may be caused 
by non-specific binding of the probe, although recent reports have suggested mechanisms 
for miRNA localization in the nucleus 39 and nucleolus 40. Furthermore, miRNA expression 
studies on a wide range of normal tissues, including normal brain and testis, using qRT-PCR, 46
Chapter 2
showed that the miR-127 and miR-17-5p expression levels are contrary to those found in 
testicular and central nervous system DLBCLs 41.
The  heterogeneous  biology  of  DLBCL  implies  that  it  is  essential  to  select 
homogeneous groups for pathogenetic studies. In our study, we used strict subsets of DLBCL 
that were proven to have been derived from three specific sites. By showing significantly 
different expression levels for miR-17-5p and miR-127 in central nervous system DLBCL and 
in testicular DLBCL, we support the assumption that each location appears to be a separate 
biological entity.Specific expression of miR-17-5p and miR-127 in testicular and central nervous system 
diffuse large B-cell lymphoma
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Abstract
The oncogenic miR-17~92 cluster contains six miRNAs (miR-17, miR-18a, miR-19a, miR-20a, 
miR-19b and miR-92a) that are expressed at variable levels in different normal and malignant 
cell types. We determined the level of the primary miR-17~92 transcript, C13ORF25, and 
the expression pattern of the six mature miRNAs in three B-cell subsets, 117 non-Hodgkin 
lymphoma (NHL) cases and 21 NHL cell lines. Within the normal B-cell subsets, significantly 
higher C13ORF25 levels were observed for naïve B cells compared to germinal center B cells. 
In the NHL cases and cell lines, BL showed the highest C13ORF25 levels. Among mature 
miRNAs, miR-92a levels were most abundant in the B-cell subsets, in the MCL, BL and CLL 
cases and all NHL cell lines. In DLBCL cases the miR-19b levels were much higher than the 
miR-92a levels. Comparison of the levels of the six mature miR-17~92 miRNAs between the 
NHL cases and their normal B-cell counterparts indicated the highest induction of miR-19b 
in cases and cell lines of the four NHL subtypes. We conclude that in normal B cells, CLL, MCL 
and BL cases miR-92a is the most abundant miRNA of the C13ORF25 transcript, whereas 
in DLBCL miR-19b showed the highest expression levels. The highest induction in NHL was 
observed for miR-19b consistent with its known oncogenic role. Marked differences in the miR-17~92 miRNA expression pattern:   
identification of miR-19b as oncogenic miRNA in non-Hodgkin lymphoma
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Introduction 
MicroRNAs  (miRNA)  are  a  class  of  noncoding  RNAs  that  are  processed  from  longer 
endogenous  primary  transcripts  (pri-miRNA).  Each  mature  miRNA  can  target  multiple 
protein-coding transcripts based on limited sequence homology, which can lead to a block 
in  translation  or to mRNA degradation.  Targeting depends  on  the degree of  sequence 
complementarity between the miRNA and target gene. Especially the seed region, i.e. 
nucleotide 2-7 at the 5’end of the miRNA, has been reported to be crucial for effective 
targeting. Several miRNAs are organized into so-called polycistrons that contain multiple 
miRNA stem loop structures in a single primary transcript. Individual miRNAs within such 
polycistronic transcripts contain the same or highly similar seed sequences in a proportion 
of miRNAs. Moreover, shared seed homology can also be observed between miRNAs of 
different or related polycistronic miRNAs 1. These miRNA seed family members are thought 
to target overlapping sets of genes.
Altered expression of miRNAs has been shown in many cancer types and miRNAs 
are located within genomic regions that show recurrent chromosomal aberrations in cancer 
2. A rapidly increasing number of miRNAs that are involved in many cancer related cellular 
processes, e.g. cell growth, cell death and angiogenesis, have been identified supporting a 
role for miRNAs in tumorigenesis 3. Moreover, several animal models indeed show a crucial 
role for miRNAs in tumorigenesis 4.
One well-known oncogenic polycistron is the miR-17~92 host gene, also known as 
C13ORF25 or Oncomir-1. C13ORF25 is located at 13q31-32 and contains six miRNAs (miR-
17, miR-18a, miR-19a, miR-20a, miR-19b and miR-92a). Each of these miRNAs has one or 
more seed family member in the C13ORF25 gene or in one of the two other homologous 
miRNA clusters 5, i.e. the miR-106a~363 cluster on chromosome X and the miR-106b~25 
cluster  on  chromosome  7.  Individual  miRNAs  from  the  miR-17~92  cluster  have  been 
shown to play a role in various cellular processes such as proliferation 6 and angiogenesis 
7 and indicate a role in cancer development. Several members of the miR-17~92 cluster 
are overexpressed in B-cell lymphoma 8, 9 and miR-17~92 has been shown to be the target 
of the 13q31-32 amplification in diffuse large B-cell lymphoma (DLBCL) 1 and mantle cell 
lymphoma (MCL)11. Further proof that members of the miR-17~92 cluster have oncogenic 
potential was obtained from studies in a MYC mouse model in which expression of miR-
17~92 accelerated lymphomagenesis 12. Besides overexpression induced by amplification 
of the 13q31-32 region, C13ORF25 was also shown to be upregulated by MYC 13. E2F1, a 
well known MYC target14, was targeted by two of the C13ORF25 miRNAs, i.e. miR-17-5p and 
miR-20a 3. This indicated a complex network between MYC, the E2F family, miR-17-5p and 54
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miR-20a 15. MiR-19a and miR-19b have been shown to be the major oncogenic components 
in the Eµ-myc transgenic mouse model of B-cell lymphoma, this was at least partly due to 
the repression of the tumor suppressor Phosphatase and tensin homolog (PTEN) 16.
The expression of individual members of polycistrons, including C13ORF25, has 
been studied in leukemia cell lines 17 and revealed marked differences between levels of 
miRNAs  derived  from  the  same  polycistrons,  suggesting  variation  in  processing  and/or 
stability of the individual miRNAs. Remarkably, in solid tumors 4, 9 as well as in lymphoma 
4, 18, often only a single miRNA or a subset of the miRNAs of the miR-17~92 cluster are 
differentially expressed.
In this study, we determined the relative abundance of the six miRNAs of the 
C13ORF25 polycistron in a NHL cohort (n=117) including Burkitt lymphoma (BL), chronic 
lymphocytic leukemia (CLL), MCL and DLBCL. The aim of this study is to analyze the expression 
patterns and to determine possible differences in these patterns in B-cell lymphoma in 
comparison to normal B-cell subsets and between NHL subtypes.
Materials and Methods
B-cell subsets. 
B  cells  were  purified  from  human  tonsils  obtained  from  children  undergoing  routine 
tonsillectomy as previously described19. Briefly, mononuclear cells were isolated by Ficoll-
Isopaque density gradient centrifugation. Monocytes and T cells were depleted by plastic 
adherence and sheep red blood cell (SRBC) rosetting, respectively. The total B cell subset 
was >97% pure as determined by FACS analyses. To sort the different B cell sub populations 
(naive B cells, memory B cells and GC B cells), cells were stained with FITC-conjugated anti-
human IgD, PE-conjugated anti-human CD20, and allophycocyanin-conjugated anti-CD38 
and sorted using a FACS aria (BD Biosciences): naive B cells (CD20+IgD+,CD38-), germinal 
center B cells (CD20+IgD-CD38+) and memory B cells (CD20+IgD-CD38-).
Patient samples.
Formaldehyde  Fixed-Paraffin  Embedded  (FFPE)  tissue  was  obtained  from  20  cases  of 
MCL, 19 cases of BL, 50 cases of primary stage I and II nodal and extranodal DLBCL and 
28 cases of CLL from the tissue bank at the Department of Pathology, University Medical 
Center Groningen and the tissue bank at the Department of Pathology, The Netherlands 
Cancer Institute, Amsterdam (a gift from Dr. D. de Jong). Each case history was reviewed 
by a hematopathologist and diagnoses were established according to the criteria of the Marked differences in the miR-17~92 miRNA expression pattern:   
identification of miR-19b as oncogenic miRNA in non-Hodgkin lymphoma
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World Health Organization classification. Only cases containing a tumor cell percentage of 
>80% were used for RNA isolation and qRT-PCR. All protocols for obtaining and studying 
human tissues and cells were approved by the institution’s review board for human subject 
research.
Cell lines. 
21 cell lines were used for the analysis, including 4 MCL cell lines (HBL-2, JEKO-1, GRANTA-519 
and UPN-1), 7 BL cell lines (Raji, CA46, BL65, NAMALWA, DG75, Jiyoye and Ramos), 6 DLBCL 
cell lines (ROSE, VER, SUDHL6, SUDHL4, OCI-Ly3 and SCHI) and 4 CLL cell lines (EHEB, MEC-
1, MEC-2 and JVM3). The mantle cell lines UPN-1 and HBL-2 were obtained from Dr. W. 
Klapper (Kiel, Germany); JEKO-1, Granta-519 and CLL cell lines JVM-3, MEC-1 and MEC-2 
were obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 
(DSMZ, Branschweig, Germany). The Burkitt cell lines DG75 and CA46 were obtained from 
the American type culture collection (ATCC) (LGC standards, Middlesex, UK). The DLBCL cell 
lines SU-DHL-4 and SU-DHL-6 were obtained from A. Epstein (UCLA, Los Angeles, CA). 
Cell lines were propagated in DMEM medium containing 10% FBS (Granta-519), 
IMDM  medium  containing  20%  (OCI-Ly3)  or  10%  (MEC-1,  MEC-2)  FBS  or  RPMI-1640 
medium containing 10% FBS (other cell lines) (Cambrex Biosciences, Walkersville, USA) 
supplemented with ultraglutamine (2mM), penicillin (100U/ml), streptomycin (0.1 mg/ml; 
Cambrex Biosciences). Cell lines were cultured at 37°C under an atmosphere containing 5% 
CO2. 
Quantitative RT-PCR. 
RNA isolation from FFPE material of DLBCL, CLL, BL and MCL cases was performed as 
described previously 20. All samples were DNAse treated using Turbo DNA free kit (Ambion, 
USA) according to the manufacturer’s instructions. Efficiency of the DNase procedure was 
checked using a multiplex PCR with 5 primer sets specific for different genomic DNA loci 
and subsequent analysis on a 1.5% agarose gel. No PCR products were seen confirming the 
effectiveness of the DNAse treatment. RNA concentrations were measured on a NanoDrop® 
ND-1000 Spectrophotometer (Nano Drop Technologies, Wilmington, Delaware, USA).
For  miRNA-specific  cDNA  synthesis  we  used  5ng  total  RNA,  the  Taqman 
MicroRNA Reverse Transcription Kit and Taqman miRNA assays for six mature miRNAs of 
the C13ORF25 cluster. The qPCR reaction was carried out on 0.44ng cDNA using miRNA 
specific primers in accordance with the instructions supplied by the manufacturer (Applied 
Biosystems, Foster City, CA, USA). The cDNA synthesis for mRNA was primed with random 
hexamer  primers  using  Superscript  II  (Invitrogen,  USA)  on  200ng  of  total  RNA.  SYBR 56
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green (Applied Biosystems) was used for the relative quantification of C13ORF25, KSRP 
with 2ng of cDNA input in a 20µl reaction. PCR reactions were performed in triplicate, 
positive  and  negative  controls  were  included  in  each  run.  Primer  sequences  used  for 
PCR  were  as  follows,  C13ORF25  forward  primer  5’-TGTGATGTTTTGTTGTGGGTTTG-3’; 
reverse  primer  5’-AGTGCTTTCTTTCCAAATATAGGC-3’.  Pri-miR-106~363  forward  primer 
5’-CAGGGATGAATGGGCAGAG-3’;  reverse  primer  5’-TGCTTCCTACGTCTGTGTGAACA-3’. 
KSRP:  forward  primer  5’-CAGAATACGAATGTGGACAAA-3’;  reverse  primer; 
5’-TCACGTTCCCGGAGGATGT-3’.  Quantification  was  performed  using  Taqman  MicroRNA 
together  with  the  7900HT  ABI  Fast  Real-Time  PCR  system  (Applied  Biosystems,  USA). 
Fluorescence was quantified with the sequence detection system software SDS (version 
2.1, Applied Biosystems, USA). Mean cycle threshold values (Ct) and standard deviations 
(SD) were calculated for all miRNAs and genes. U6 was selected as a housekeeping gene to 
normalize the mRNA and miRNA levels as it showed a uniform expression level in all samples 
and a sufficiently low threshold Ct value. Cases with a Ct value for U6 > 30 were regarded to 
have bad RNA quality and therefore excluded from further analysis. The relative expression 
levels were expressed as 2-ΔCt. 
 Given the large number of NHL samples (n=119), qRT-PCR of the NHL cases was 
performed in separate runs for each of the four subtypes. The comparative threshold cycle 
method was applied using RNA isolated from a pediatric tonsil obtained during routine 
tonsillectomy as endogenous reference using the formula 2-ΔΔCt (ΔΔCt = (Ct sample - Ct U6 sample) 
- (ΔCt Tonsil - ΔCt U6 Tonsil). To allow comparison of the levels of the individual members of the 
miR-17~92 cluster the sum of the 2-ΔCt values were set at 100%. 
 To determine the efficiency of the miRNA qPCR, a 2x serial dilution of cDNA of a 
cell line with relatively high expression of each of the miRNAs was used in a qPCR reaction. 
The amplification efficiency was calculated based on the dependence of the Ct value on the 
cDNA dilution using the following equation: .
Immunohistochemistry. HnRNP A1 was stained using ab50492 (Abcam, Cambridge, 
UK) with tris/EDTA pre-treatment and a 1:100 antibody dilution followed by detection with 
labeled GaRPO followed by RaGPO and DAB substrate chromagen solution. Slides were 
lightly counter-stained with hematoxylin before imaging.
Data analysis. 
To determine significant differences in C13ORF25 and individual miRNAs levels within each 
NHL subtype a Kruskal-Wallis test was performed with a Dunn’s Multiple Comparison Test 
and a p-value <0.05 was considered significant (GraphPad Prism software, version 5.04). 
To determine the association between the primary transcript and mature miRNA, Pearson Marked differences in the miR-17~92 miRNA expression pattern:   
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and Spearman’s rank correlations together with univariate linear regression were used. A 
p-value <0.05 was considered significant.
Results
Levels of C13ORF25 vary in B-cell NHL
C13ORF25 levels were determined by qRT-PCR in normal B-cell subsets, in 117 B-cell NHL 
samples, including 20 MCL, 19 BL, 50 DLBCL and 28 CLL cases, and in 21 B-cell NHL-derived 
cell  lines.  Within  the  normal  B-cell  subsets,  a  significantly  higher  C13ORF25  level  was 
observed for naïve B cells compared to GC B cells (p<0.05) (Fig. 1A). C13ORF25 expression 
within the 117 NHL subtypes revealed marked differences between the four NHL subtypes 
(Fig. 1B). The levels were the highest in BL and the lowest in CLL (9 fold difference) with 
marked differences in expression levels between individual cases of each NHL subtype. 
The BL cases showed a significantly higher C13ORF25 level compared to CLL (p<0.001) and 
MCL (p<0.01). We also observed a significant difference between DLBCL and CLL (p<0.001). 
The overall pattern observed in the NHL cell lines was similar to the NHL cases, but the 
differences between NHL subtypes were not significant (Fig. 1C) probably due to smaller 
group sizes. The BL cell lines showed the highest levels of C13ORF25, followed by MCL and 
CLL cell lines, whereas DLBCL cell lines had the lowest levels.
Different levels of the miR-17~92 cluster members in B-cell NHL 
We next studied the levels of the six individual members of the C13ORF25 cluster, i.e. 
miR-17, miR-18a, miR-19a, miR-20a, miR-19b and miR-92a. Each B-cell subset showed a 
similar pattern with the highest level observed for miR-92a (up to 60% of the total of all 
miR-17~92 members together) and the lowest levels for miR-18a and miR-19b (less than 
1%) (Fig. 2A). miR-92a levels were significantly higher than the levels of the other miRNAs 
in all three B-cell subsets (p< 0.01). The NHL cases also had significant differences in the 
levels of each of the six miR-17~92 cluster members. For MCL, BL and CLL, miR-92a was 
the most abundant miRNA (60-80%) followed by miR-19b (10-30%). In DLBCL, miR-19b was 
most abundant (~60%), whereas miR-92a levels were much lower (<20%), in the same range 
as miR-20a and miR-19a.
The cell lines derived from the four NHL subsets showed similar expression patterns, 
with miR-92a being the most abundant cluster member (45-73%). MiR-19b was the second 
most abundant in BL and DLBCL (~21%). In MCL, miR-19b and miR-20a levels were similar 58
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 ﾠ
Figure 1. Expression levels of C13ORF25 in normal and malignant B cells. (A) The normal B-cell subsets 
showed a significant difference in the primary miR-17~92 transcript levels only between naïve and GC 
B-cell subsets. (B) The B-cell malignancies showed significantly different C13ORF25 levels that were 
the highest in BL and the lowest in CLL. C13ORF25 levels were normalized to an external common 
calibrator using a comparative threshold cycle method to allow comparison of the levels between 
the four B-cell malignancies. (C) In the BL cell lines, the levels of C13ORF25 were significantly higher 
compared to the DLBCL cell lines. P values were determined using a Kruskal-Wallis test. (*p<0.05, 
**p<0.01, ***p<0.001).
 ﾠ Figure 2. Expression patterns of miR-17~92 miRNAs in B cells and NHL. (A) In the normal B-cell subsets 
miR-92a levels are significantly higher as compared to the levels of the five other miRNAs. (B) The 
B-cell malignancies MCL, BL and CLL showed the highest levels of miR-92a, whereas in DLBCL a higher 
level was observed for miR-19b. (C) The cell lines also showed significant differences within the miR-
17~92 cluster with the highest levels for miR-92a. P values were determined using a Kruskal-Wallis 
test. Marked differences in the miR-17~92 miRNA expression pattern:   
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(~22%) and were the second/third most abundant miRNAs in MCL. In CLL, four of the five 
remaining miRNAs showed similar low levels (3-8%).
We next studied the correlation between the levels of the six mature miRNAs and 
the C13ORF25 levels for all NHL cases and cell lines. BL cases showed a significant correlation 
for five of the six miRNAs, i.e. miR-18a (r=0.50, p=0.03), miR-19a (r=0.50, p=0.03), miR-
20a (r=0.55, p=0.01), miR-19b (r=0,92; p<0.0001) and miR-92a (r=0.70, p=0.0008) (Fig. 3A). 
Correlations for the other NHL subtypes were less pronounced, with a significant association 
observed for miR-92a in MCL, miR-20a in DLBCL, miR-17 and miR-19a in CLL. In the NHL cell 
lines (Fig. 3B) only two significant associations were observed, which is probably due to the 
lower number of cell lines studied. Both significant associations were observed in BL cell 
lines, i.e. miR-19b (r=0.93, p=0.007) and miR-92a (r=0.82, p=0.003).
A  possible  explanation  for  the  marked  differences  in  expression  of  individual 
cluster members might be caused by differences in efficiency of the qRT-PCR procedure. 
Therefore, we tested the efficiency of the Taqman miRNA assays on serial dilutions of cDNA 
from the BL-derived CA46 cell line that had a relative high expression level of all six cluster 
members. The efficiency ranged from 103% to 109% (Supplementary Fig. 1), with the highest 
efficiency for miR-17 and the lowest efficiency for both miR-18a and miR-92a. Thus, based 
on these efficiencies it is highly unlikely that the high miR-92a levels are caused by efficiency 
differences in the qRT-PCR. 
A second explanation for the observed differences might be a high or variable 
expression of the homologous pri-miR-106a~363 transcript that contains two precursor 
sequences that are highly homologous to the C13ORF25 precursors of miR-92a and miR-
19b and result in identical mature miR-92a and miR-19b. To compare both transcripts, qRT-
PCR was performed on 7 MCL, 7 BL, 7 DLBCL and 5 CLL cases. In comparison to the high 
expression levels of C13ORF25, the levels of pri-miR-106a~363 were much lower (range 
4 to 20 fold) (Supplementary Fig. 2). This indicates that it is unlikely that the high levels of 
miR-92a and miR-19b in comparison to the other members of the C13ORF25 cluster can be 
explained by expression of the homologous pri-miR-106~363 cluster.
A third possibility is that factors influencing the processing efficiency or stability of 
the individual miRNAs cause differences in mature miRNA levels. KH-type splicing regulatory 
protein (KSRP) and the RNA binding protein heterogeneous nuclear ribonucleoprotein A1 
(HnRNP A1) have been reported to regulate processing of miR-20a and miR-18a, respectively. 
To identify a possible relation between KSRP levels and the levels of miR-20a, we performed 
qRT-PCR on 3 MCL, 12 DLBCL, 6 BL, 9 CLL. No relation was observed between KSRP levels and 
the mature miR-20a levels (data not shown). Immunohistochemical staining of HnRNP A1 
in NHL cases showed no difference in expression between tumors with high or low miR-18a 
levels (data not shown).60
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 ﾠ Figure 3. Correlation of C13ORF25 levels with the levels of the six individual miRNAs. (A) In the NHL 
cases correlations were seen in each of the four NHL subtypes. In MCL and DLBCL, miR-92a showed a 
significant correlation with C13ORF25 levels. In BL a significant correlation was seen for five out of the 
six miRNAs whereas in CLL miR-17 and miR-19a levels showed significant correlations with C13ORF25 
levels. (B) In the NHL cell lines only two significant correlations were observed, i.e. for miR-19b and 
miR-92a in the BL cell lines. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.Marked differences in the miR-17~92 miRNA expression pattern:   
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Fold induction levels in NHL subtypes 
To determine whether the levels of the members of the miR-17~92 cluster are deregulated 
in NHL we studied the fold induction of the miR-17~92 cluster members for each NHL 
subtype in relation to their normal B-cell counterparts (Fig. 4). The fold induction of all miR-
17~92 cluster members as compared to their normal counter parts were increased albeit 
at variable levels. The strongest fold increases were observed for miR-19b in all four NHL 
subtypes with fold inductions varying from 10 for CLL compared to memory B cells to 415 for 
MCL compared to naïve B cells. For the cell lines the fold increase ranged from 746-fold for 
CLL compared to memory B cells, to 1344-fold for DLBCL compared to GC B cells. For the five 
other members of the miR-17~92 cluster the fold increase in comparison to normal B cells 
ranged from 1 to 21 fold for the NHL cases and from 5 to 643 fold for the cell lines. Despite 
the marked high levels of miR-92a, there was no apparent fold increase as compared to 
normal B cell subsets. Thus, miR-19b is the most pronounced upregulated member of the 
miR-17~92 cluster in NHL.
 ﾠ
Figure 4. Fold induction levels in NHL subtypes. Levels of the mature miRNAs in the NHL cases are 
given relative to the levels of the mature miRNAs in their normal B-cell counterparts.  The cases all 
showed a significant fold increase in the expression levels of miR-19b (p<0.001). The cell lines also 
showed a significant fold increase in the expression of miR-19b (p<0.05). P values were determined 
using a Kruskal-Wallis test.62
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Discussion
In this study we analyzed the expression pattern of the 6 miRNAs that are processed from 
the noncoding C13ORF25 transcript in NHL. We showed that normal B cells and each of the 
four NHL subtypes have a distinct expression pattern for the six miRNAs. MiR-92a was the 
most abundant miRNA in the normal B-cell subsets and three of the four NHL subtypes, 
whereas miR-19b was the most abundant cluster member in DLBCL. In comparison to their 
normal B cell counterparts, all NHL subtypes showed the strongest fold-increase for the 
oncogenic miR-19b.
MYC  and  13q31-32  amplification  are  two  well-known  mechanisms  to  induce 
C13ORF25 in NHL 21, 3, 10, 22. We observed significantly different C13ORF25 levels in each of the 
four NHL subtypes. BL cases showed the highest C13ORF25 levels, which is consistent with 
the genetic hallmark of BL; a translocation of the MYC locus to one of the immunoglobulin 
loci. The variations in C13ORF25 levels observed between and within each NHL subtype 
are  most  likely  caused  by  differences  in  MYC  levels  and/or  the  presence  of  13q31-32 
amplifications in individual cases. 
The most abundant miR-17~92 cluster members in B cells and NHL were miR-92a 
and miR-19b. The miR-106a~363 cluster contains miRNAs that are identical to miR-19b and 
miR-92a derived from the miR-17~92 cluster  23. In the NHL cases the level of C13ORF25 
was always much higher than the level of pri-miR-106a~363. Thus, despite the presence 
of a homologue cluster that also contains miR-19b and miR-92a, it is unlikely that the 
higher miR-92a and miR-19b levels in comparison to the four other C13ORF25 members 
can be explained by co-expression of the pri-miR-106a~363 cluster. We next examined the 
correlation between the primary miRNA transcript and the mature miRNAs to assess possible 
differences in the biogenesis or stability of individual miRNAs. BL showed a good correlation 
between C13ORF25 and five of the six cluster members, in the other NHL subtypes the 
correlation was less obvious. A poor correlation between primary transcript and mature 
miRNAs has been reported for miR-138 in murine brain and murine neuroblastoma cell 
line N2A 24, let-7 in  neural  cell  specification  25 and  miR-143 and  miR-145 in  colorectal 
adenocarcionoma  26. These studies indicate that the levels of primary transcripts do not 
necessarily correlate with the levels of mature miRNAs.
Two RNA binding proteins, i.e. KSRP and hnRNP A1, have been shown to be involved 
in biogenesis of certain members of the miR-17~92 cluster. HnRNP A1 facilitates processing 
of miRNA-18a 27 and KSRP enhances biogenesis of a group of miRNAs including miR-20a and 
miR-106a 28, 29. We observed no difference in hnRNP A1 staining intensity between tumors 
with high and low miR-18a levels, indicating that differences in miR-18a levels are not likely Marked differences in the miR-17~92 miRNA expression pattern:   
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due to differences in hnRNP A1 expression. This might, in part, be caused by the overall low 
miR-18a levels observed in NHL. Since there was no antibody available that showed a good 
staining pattern on FFPE tissue sections, we analyzed KRSP by qRT-PCR. KRSP levels showed 
no relationship to miR-20a expression on a selection of the NHL cases with variable miR-20a 
levels. There are currently no known factors that affect biogenesis of miR-19a, miR-19b or 
miR-92a. Chaulk et al showed that the tertiary structure of the miR-17~92 transcript in vitro 
is organized in such a way that the miR-92a and miR-19b stem-loops are internalized making 
them less accessible and thus less efficiently processed 30. It would be interesting to analyze 
the structure of this primary transcript in B cells or in NHL cell lines to establish if in this cell 
type the miR-92a and miR-19b stem-loops are more accessible for processing. Moreover, it 
may be speculated that despite lower pri-miR-106a~363 levels, accessibility of miR-19b and 
miR-92a is much better in this transcript, and that a substantial proportion of the mature 
miR-19b and miR-92a miRNAs are derived from this transcript despite its lower levels. 
We observed that miR-92a was the most abundant miRNA in the B-cell subsets, 
the MCL, BL and CLL cases and in the NHL cell lines. MiR-19b usually was the second most 
abundant miRNA in the NHL cases and cell lines. In contrast to the MCL, BL and CLL cases, 
the DLBCL cases showed the highest levels for miR-19b. Analysis of the individual DLBCL 
cases showed that in 49 of the 50 cases the miR-19b levels were indeed higher than the miR-
92a levels (Supplementary Fig. 3). MiR-92a has been shown to be involved in carcinogenesis 
by suppression of angiogenesis by targeting Integrin α5 (ITGA5) 31 and by affecting cellular 
proliferation in colon and hepatocellular carcinoma cell lines 9.  MiR-92a is overexpressed 
in a wide variety of cancers, but a role in B-cell lymphomagenesis is less evident. MiR-92a 
is usually not among the consistently overexpressed miRNAs in profiling studies in NHL 32-34. 
He et al. demonstrated that overexpression of a truncated miR-17~19b cluster, thus without 
miR-92a, cooperates with MYC to promote lymphomagenesis in mouse models  12. This 
indicates that miR-92a is not essential for the oncogenic effect of the miR-17~92 cluster. We 
observed no specific induction of miR-92a in comparison to their normal B cell counterparts, 
despite the high miR-92a levels observed in the majority of the NHL cases. Thus, it is unlikely 
that miR-92a plays a main role in NHL lymphomagenesis.
Finally, we assessed the putative oncogenic changes of the mature miRNA levels 
in relation to their normal counterparts. For all four NHL subtypes, miR-19b showed the 
highest fold increase ranging from 10- to ~1300-fold. It is unclear why only miR-19b and not 
the closely related miR-19a is induced in the NHL cases and cell lines. This might indicate 
that targets specific for miR-19b play a role in lymphomagenesis. MiR-19b, together with 
miR-19a, accelerated the MYC-induced lymphomagenesis in transgenic mice models 16, 34. 
MiR-19a and miR-19b have also been shown to be significantly upregulated in Cyclin D1-64
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positive MCL patients 35.  Proven targets of miR-19b include protein kinase, AMP-activated, 
alpha  1  catalytic  subunit  (Prkaa1),  protein  phosphatase  2  (PP2a),  Bcl-2-like  protein  11 
(Bim)  36, pro-angiogenic protein FGFR2  37 and the tumor suppressor gene PTEN  38. PTEN 
negatively regulates the phosphatidylinosiol-3-kinase (PI3K) pathway  38 and activation of 
the PI3K pathway is a key element for the malignant transformation of MYC expressing 
germinal center B cells in a BL mouse model 39. Overall, there is strong evidence that miR-
19a and miR-19b are important oncogenic miRNAs in NHL pathogenesis. The mechanism 
of specific upregulation of miR-19b and not the other members of the miR-17-92 cluster in 
NHL compared to normal B cells is not yet known. 
In conclusion, we showed that miR-92a is the most abundant miRNA of the miR-
17~92 cluster, in normal B cells, CLL, MCL and BL cases. In DLBCL, miR-19b showed the 
highest levels, and miR-92a was the second most abundant miRNA. Despite high miR-
92a levels, we observed the highest fold induction for miR-19b in all four NHL subtypes in 
comparison to their normal B-cell counterparts, consistent with its known oncogenic role.Marked differences in the miR-17~92 miRNA expression pattern:   
identification of miR-19b as oncogenic miRNA in non-Hodgkin lymphoma
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Supplementary Figures
SUPPLEMENTARY FIGURE 1. Relative expression of C13ORF25 and pri-miR-106a~363. In the 
four NHL subtypes C13ORF25 levels were higher than the levels of the homolog pri-miR-
106a~363 cluster.
SUPPLEMENTARY FIGURE 2. Efficiency of qRT-PCR procedure. Using 
a sample with relative high levels of all six cluster members the PCR 
efficiency was determined. The efficiencies ranged from 103% for 
miR-92a to 109% for miR-17. 
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SUPPLEMENTARY FIGURE 3. Expression levels of miR-19b and miR-92a in individual DLBCL cases. To 
determine if the relative high expression of miR-19b in contrast to miR-92a is due to extreme outliers, 
the levels of both miRNAs were compared separately for each DLBCL case. Only one DLBCL case 
showed a higher level of miR-92a compared to miR-19b.71
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Abstract
Recent studies have indicated the importance of miRNAs in B cell maturation and also in 
the development of B cell lymphoma. To obtain insight into the role of miRNAs in B cell 
lymphoma we determined the miRNA expression profile of four normal B cell subsets, 
mantle cell lymphoma (MCL), follicular lymphoma (FL), paediatric Burkitt lymphoma (BL) and 
chronic lymphocytic lymphoma (CLL). Unsupervised clustering revealed two main clusters, 
i.e. one for normal B cell subsets and one for the four lymphoma samples. In the B cell 
subsets, 23 differentially expressed miRNAs were identified with the most specific patterns 
for GC B cells and plasma cells. 73 miRNAs were differentially expressed between the four 
NHL, with the most discriminating pattern for BL. Since BL are characterized by high MYC 
expression and frequently have 13q31 amplification, we determined differential expression 
of 49 of the 60 miRNAs known to be regulated by MYC. A significant down- or upregulation 
was observed for 39 (80%) of these miRNAs in the BL compared to the other NHL. High 
expression of the MYC inducible miR-17-92 cluster members was strongly associated with 
13q31 amplification. In conclusion, the most characteristic miRNA profile was observed for 
BL and included many MYC regulated miRNAs, consistent with the presence of a t(8;14) and 
a high MYC expression in all BL cases.
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Introduction
Several studies have indicated the importance of miRNAs in B cell maturation and in the 
development of B cell lymphomas. The oncogene MYC plays an important role in B cell 
lymphomagenesis, particularly in Burkitt lymphoma (BL). Several recent publications have 
shown that MYC regulates expression of up to 60 miRNAs (Tables I and SI). The impact of 
the translocation and overexpression of MYC on the miRNA profile in BL has not yet been 
explored. We determined the miRNA expression profile of paediatric t(8;14) positive and 
high MYC expressing BL in comparison to MYC translocation negative mantle cell lymphoma 
(MCL), follicular lymphoma (FL) and chronic lymphocytic leukaemia (CLL). As a control we 
included normal B cell subsets obtained from hyperplastic tonsils.
Table I.  Known   MYC regulated miRNAs and differential expression between BL versus CLL, MCL and 
FL.
miRNA Significant differences between BL and other NHL
Flagged P-value Corrected P-value Regulation Fold change
Induced
miR-7 Yes 0·0264 0·0340 Up 2
miR-17-3p Yes ns
miR-17-5p Yes 0·0264 0·0340 Up 2
miR-18a Yes 0·0004 0·0011 Up 4
miR-19a Yes 0·0138 0·0188 Up 3
miR-19b Yes ns
miR-20a Yes 0·0298 0·0375 Up 2
miR-20b Yes ns
miR-92 Yes ns
miR-106a Yes 0·0105 0·0161 Up 2
miR-128b Yes ns
miR-130b Yes 0·0038 0·0064 Up 3
miR-206 Yes ns
miR-213 No
miR-370 Yes 0·0138 0·0188 Up 2
miR-422a No
miR-468 No
Repressed
let-7e Yes 0·0002 0·0010 Down 4
miR-15a Yes 0·0038 0·0064 Down 3
miR-16 Yes 0·0017 0·0035 Down 2
miR-22 Yes 0·0138 0·0188 Down 274
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Table I.  Known   MYC regulated miRNAs and differential expression between BL versus CLL, MCL and 
FL.
miRNA Significant differences between BL and other NHL
Flagged P-value Corrected P-value Regulation Fold change
miR-23a Yes 0·0005 0·0013 Down 2
miR-23b Yes 0·0038 0·0064 Down 2
miR-24 Yes 0·0002 0·0010 Down 3
miR-26a Yes 0·0002 0·0010 Down 7
miR-26b Yes 0·0002 0·0010 Down 4
miR-29a Yes 0·0002 0·0010 Down 9
miR-29b Yes 0·0002 0·0010 Down 8
miR-29c Yes 0·0002 0·0010 Down 16
miR-30c Yes 0·0059 0·0094 Down 2
miR-30e-3p Yes 0·0051 0·0083 Down 3
miR-30e-5p Yes 0·0002 0·0010 Down 6
miR-34a Yes 0·0006 0·0015 Down 2
miR-99b Yes 0·0014 0·0031 Down 3
miR-101a Yes 0·0003 0·0010 Down 6
miR-125b Yes 0·0004 0·0012 Down 2
miR-134 No
miR-139 Yes 0·0004 0·0011 Down 7
miR-140 Yes 0·0121 0·0179 Down 3
miR-142-3p Yes 0·0032 0·0061 Down 4
miR-144 Yes ns
miR-146a Yes 0·0004 0·0012 Down 5
miR-150 Yes 0·0002 0·0010 Down 45
miR-195 Yes 0·0002 0·0010 Down 5
miR-207 No
miR-210 Yes ns
miR-215 Yes ns
miR-223 Yes 0·0009 0·0020 Down 4
miR-342 Yes 0·0002 0·0010 Down 3
miR-451 Yes ns
miR-466 No
miR-467 No
miR-489 No
miR-494 Yes 0·0020 0·0039 Up 3
LET-7A Yes 0·0002 0·0010 Down 3
miR-124 No
miR-148 Yes ns
miR-155 Yes 0·0003 0·0010 Down 8
miR-196 Yes 0·0012 0·0027 Down 4
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Results
Hierarchical clustering showed that the B cell subsets and the non-Hodgkin lymphomas 
(NHLs) formed two distinct sub-clusters (Fig 1). Unsupervised clustering of the 23 miRNAs 
significantly differentially expressed between the four B cell subsets (>4-fold) revealed one 
cluster for the naïve and memory B cells and two additional clusters for the germinal centre 
(GC) B cells and plasma cells. These results were consistent with previously published data 
(Appendix S1). 76 miRNAs were differentially expressed (>4-fold) between the four NHL 
subtypes. Most differences were observed between BL and the other NHLs (CLL n = 58, FL 
n = 32 and MCL n = 36 miRNAs). Unsupervised hierarchical clustering analysis revealed a 
unique miRNA profile in BL (Appendix S2). In contrast, a maximum of eight miRNAs were 
differently expressed between MCL, FL and CLL. A list of validated target genes of the 
differentially expressed miRNAs is presented in Table SII. Comparing each malignancy to its 
normal counterpart (MCL with naïve, FL and BL with GC B cells and CLL with memory cells), 
54–77 miRNAs were differentially expressed (Figure S1).
Of the 60 reported MYC regulated miRNAs (Table I), 50 were expressed in at least 
three of the NHL samples and therefore considered to be evaluable. A significant difference 
between the high MYC BL and the other low MYC lymphoma samples was observed for 
39 miRNAs. The miRNA pattern in BL is consistent with the expected MYC regulation. CLL 
showed an almost inversed pattern. MCL and FL showed intermediate pattern. *, indicates 
miRNAs with a proven MYC binding site in the promoter region. 
MYC expression has been shown to be a dominant factor in the regulation of many 
miRNAs. In the present series of lymphomas, quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) showed a much higher expression in BL than all other NHL (Fig 1C). 
Comparison of the MYC-high BL to all other MYC-low lymphomas revealed 122 differentially 
expressed miRNAs (Table SIII), including 39 of the 50 evaluable (78%) known targets of MYC 
(10 miRNAs were not expressed in our cases) (Fig 1D and Table I). The expression level 
of these 39 miRNAs was always consistent with the expected up- or downregulation, with 
most miRNAs being downregulated. This indicates a dominant MYC-induced miRNA profile 
in primary BL. This signature included 39 of the known MYC-regulated miRNAs. The 83 other 
miRNAs were also differentially expressed between MYC-high BL and MYC-low NHL samples. 
At present, there are no data supporting a direct MYC-dependent regulation for those 83 
miRNAs. A MYC-dependent miRNA signature has also been suggested for diffuse large B cell 
lymphoma based on a differential expression of MYC targets 1.
Four BL cases (B4, B5, B6 and B7) and two MCL cases (M2 and M3) harboured a 
13q31.3 amplification (determined by fluorescence in situ hybridization, results not shown). 76
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These six cases showed high expression of the miR-17-92 cluster (Fig 1D). Both in BL and 
MCL, this association was independent of the MYC expression level (Fig 1C). In line with 
the findings of Tagawa et al (2007) 2 this indicates that genomic amplification and not MYC 
overexpression is instrumental in the expression of the miR-17-92 cluster.
Discussion
The  miR-17-92  cluster  is  positively  regulated  by  MYC  and  acts  with  MYC to accelerate 
tumour development 3. MiR-17 and miR-20, two members of this cluster, promote cell cycle 
progression via E2F1 4. One interesting MYC-repressed gene is MIRLET7A. As MYC is a direct 
target of MIRLET7A this suggests a positive stimulatory loop for MYC 5. Induction of MIRLET7A 
in the Namalwa BL cell line resulted in reduced MYC expression and reduced proliferation, 
whereas downregulation of MYC resulted in increased expression of MIRLET7A. In addition 
to a significant downregulation of MIRLET7A, we also observed a significant downregulation 
for MIRLET7E in BL compared to the three other NHL subtypes. MiR-150 was also significantly 
downregulated in BL and targets MYB, which has an essential role in haematopoietic and 
lymphoid development and apoptosis  6. Overexpression of miR-150 in BL cells resulted in 
reduced MYB levels and increased apoptosis 7. Interestingly miR-15a has recently also been 
shown to repress the MYB oncogene in leukemic cell lines 8 . Low expression of miR-150 in BL 
compared to the other three NHL subtypes and of miR-15a in comparison to CLL might thus 
result in enhanced MYB levels in BL. Ectopic expression of miR-26a in BL cell lines impaired cell 
cycle progression via its target EZH2, a member of the polycomb-group of genes 9. The low 
expression of miR-26a in BL is thus consistent with the previously observed high expression 
of EZH2 in BL. Concurrent with previous reports, we found downregulation of miR-155 in 
BL. Although it is unclear which target gene(s) promote tumorigenesis in lymphomas, loss 
of the miR-155 dependent regulatory control of activation-induced cytidine deaminase (AID) 
expression, by the introduction of a point mutation in the miR-155 binding site, resulted in 
increased levels of AID and a higher frequency of MYC translocations 10. This is consistent with 
low miR-155 levels in MYC/8q24 translocation-positive BL. Finally, several other MYC-regulated 
miRNAs have been implicated in B cell lymphoma and were found to be downregulated in 
BL e.g. miR-23a/b targeting glutaminase, miR-125b targeting IRF4 and PRDM1/BLIMP1, miR-
146a targeting IRAK1 and TRAF6 and miR-223 targeting LMO2 (Table SII).
To  conclude,  this  study  showed  a  very  characteristic  MYC-induced  miRNA 
expression profile in BL. This indicates that MYC regulates BL cell fate in a direct mode at 
the transcriptional level and indirectly at the translational level by influencing the miRNA 
profile. Our data support previous studies showing MYC-induced miRNA changes in cell lines 
and animal models.MiRNA profiling in B cell non-Hodgkin lymphoma:   
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 ﾠ Figure 1.    Heatmap of the unsupervised hierarchical clustering of all miRNAs and miRNAs that are 
MYC-regulated. MiRNA profiles were generated using Agilent Oligo Microarray Kit (G4470A; Agilent, 
Santa Clara, CA, USA) and the protocol provided by the manufacturer. In total, 256 out of the 556 
human miRNAs were expressed in at least three out of the 44 samples. (A) Heatmap of 256 miRNAs 
expressed in at least three samples. (B) Enlargement of the clustering tree. With the exception of one 
FL sample (#FL2) all normal B cell samples cluster separately from the lymphoma samples. (C) Box 
plot of the MYC expression levels in BL, CLL MCL determined by qRT-PCR. High MYC expression levels 
were observed in all six MYC translocation-positive BL, whereas the MYC levels were much lower in 
MCL, CLL and FL.). (D) Heatmap of the MYC induced miRNAs; MYC induced and repressed miRNAs are 
indicated on the right-hand side. 78
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Supplementary figures
Appendix S1: B cell subsets
Approach
Naïve,  germinal  center  (GC),  memory  and  plasma  cells  were  purified  from  3  human 
tonsils obtained from children undergoing routine tonsillectomy resulting in a total of 12 
B cell samples. Briefly, mononuclear cells were isolated by Ficoll-Isopaque density gradient 
centrifugation. Monocytes and T cells were depleted by plastic adherence and SRBC rosetting, 
respectively. The total B cells fraction was >97% pure as determined by FACS analysis. B 
cells were stained with FITC-conjugated anti-human IgD, PE-conjugated anti-human CD20, 
and allophycocyanin-conjugated anti-CD38 and sorted using a FACS aria (BD Biosciences) in: 
naive B cells (IgD+,CD38-), GC B cells (IgD-CD38+), plasma cells (IgD-,CD38++) and memory 
B cells (IgD-,CD38-).
Microarray analysis was performed using the G4470A Agilent Oligo Microarray Kit 
(G4470A;  Agilent,  Santa  Clara,  USA)  and  the  protocol  provided  by  the  company  Data 
were analyzed  using  GeneSpring  GX10.0  software (Agilent, Santa  Clara, USA)  following 
the manufacturers recommendations. Raw data were normalized using a shift to the 75th 
percentile, without a baseline transformation. Unsupervised clustering analysis of miRNA 
expression  data  was  performed  using  Genesis.    After  median  centring  of  the  miRNA 
expression data over all samples, complete similarity metrics were calculated and clustering 
was performed using Euclidean distance and average linkage. One way ANOVA with a post 
hoc Tukey Honestly Significantly Different (HSD) test and Benjamini Hochberg false discovery 
rate  (FDR)  correction  were  performed  to  identify  significantly  differentially  expressed 
miRNAs. Differences in miRNAs were considered statistically significant if the P value was 
less than 0.05. To identify biologically relevant miRNAs a fold change in expression level of 
at least 4.0 was taken as a cut off.
Results
Out of the 127 miRNAs expressed in the four mature B cell subsets isolated from hyperplastic 
tonsils, 23 were >4 fold differentially expressed between the different populations (Table 1). 
Only a single miRNA, i.e. miR-146a, was differentially expressed between naïve and memory 
B cells using ANOVA and a four fold difference as selection criteria. Relaxing the criteria 
to only ANOVA did not reveal any additional miRNAs. Unsupervised clustering of the 23 
differentially expressed miRNAs revealed one cluster for the naïve and memory B cells and 80
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two additional clusters for the GC and plasma cells (Fig. 1). These data were consistently 
with previously published studies also showing a rather similar miRNA expression pattern 
in naïve and memory cells as compared to centroblasts or germinal center B cells (Lawrie 
et al, 2007;Malumbres et al, 2008;Basso et al., 2009;Tan et al., 2009;Zhang et al., 2009). 
Heatmaps generated for the miRNAs differentially expressed in these studies using our 
microarray data data revealed similar miRNA expression patterns (Figures 2, 3 and 4) 1-3. 
Table 1. Overview of the 23 miRNAs differentially expressed in B cell subsets. 
Fold Naïve B cells Memory cells Plasma cells
Naïve B cells
up  >16
8-16
4-8 miR-146a
down 4-8
8-16
>16
GC B cells
up >16 miR-148a
8-16 miR-15a, miR-93,  miR-
130b, miR-193 
miR-148a miR-28, miR-93, 
miR-151, miR-222
4-8 miR-22,   miR-28,  miR-
146a,  miR-301, miR-331, 
miR-425-5p, miR-454-3p 
miR-15b, miR-28,  miR-93,  
miR-106a,  miR-130b, miR-
301, miR-331, miR-454-3p, 
miR-425-5p
miR-7, miR-17-5p, 
miR-106a,  miR-
221, miR-425-5p
down 4-8 miR-768-3p, miR-768-5p miR-150,  miR-768-3p miR-193b
8-16 miR-150 miR-22, miR-148a
>16
Plasma cells
up  >16 miR-22, miR-148a, miR-
193b
miR-22, miR-148a, miR-193b
8-16 miR-130b
4-8 miR-146a miR-130b, miR-331, miR-365
down 4-8 miR-342, miR-151, miR-
768-5p
miR-342, miR-221
8-16 miR-150, miR-221,  miR-
222
miR-222 
>16 miR-150
Five of the miRNAs, i.e. miR-146a, miR-150, miR-193b, miR-221 and miR-222, differentially 
expressed between the four normal B cell subsets, also show significant differences between 
the four lymphoma subsets (Supplementary file 2). MiRNA profiling in B cell non-Hodgkin lymphoma:   
a MYC-related miRNA profile characterizes Burkitt lymphoma
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Figure 1. Heatmap of the unsupervised hierarchical clustering of the miRNAs differentially expressed 
in naïve, GC, memory and plasma cells. Both naïve and memory B cells show a similar expression 
pattern, whereas GC B cells and plasma cells each show a more distinct profile. 
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Figure 2. Expression pattern of the classifier miRNA subset from Malubres et al., (2008) in our data 
set. A, Heatmap of our data for the miRNAs described by Malubres et al. .B, Heatmap of Malubres et 
al. To allow a better comparison only the three B cell subsets analyzed in both studies are shown, i.e. 
GC B, memory and naïve in our study and centroblasts, memory cells and naïve cells in the study by 
Malubres et al. 
 ﾠ A  B 
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Figure 3. Comparison to Zhang et al., (2009). A, heatmap of our data for the miRNAs described by 
Zhang et al, B, data of Zhang et al. Since the online data are not available yet we only show the 
heatmap for the miRNAs specifically mentioned in the paper of Zhang et al. 
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Figure 4. Comparison to Basso et al., (2009). A, Heatmap of our data for the miRNAs described by 
Basso et al. B, Heatmap of Basso et al. To allow a better comparison the three B cell subsets analyzed 
in both studies are shown, i.e. GC B, memory and naïve in our study and centroblasts, memory cells 
and naïve cells in the study by Basso et al. 
 ﾠ
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Appendix S2: NHL subsets
Approach
Specimens of frozen lymph nodes of 32 patients were collected from the UMCG tissue bank. 
Each individual diagnosis was reviewed by an experienced haematopathologist according 
to the classification of the WHO. The lymphoma samples were selected to have at least 
60% tumor cells and each case was selected by strict definition according to the WHO 
classification. The samples were derived from 6 patients with BL (all paediatric patients with 
an abdominal mass, phenotype: CD10+, BCL2- and EBV- and carrying a MYC/8q24 breakpoint 
as assessed by fluorescence in situ hybridization), 7 patients with FL (all nodal, CD10+, CD5-, 
BCL2+ and grade 1 or 2), 7 patients with MCL (all nodal, CD5+ and cyclinD1+) and 12 patients 
with CLL (all nodal, CD5+ and CD23+, and cyclinD1-; 8 cases were ZAP70+ and 4 ZAP70-). 
Microarray analysis was performed using the G4470A Agilent Oligo Microarray Kit 
(G4470A;  Agilent,  Santa  Clara,  USA)  and  the  protocol  provided  by  the  company  Data 
were analyzed  using  GeneSpring  GX10.0  software (Agilent, Santa  Clara, USA)  following 
the  manufacturers  recommendations.  Raw  data  were  normalized  using  a  shift  to  the 
75th  percentile,  without  a  baseline  transformation.  Unsupervised  clustering  analysis  of 
miRNA  expression  data  was  performed  using  Genesis.    After  median  centring  of  the 
miRNA expression data over all samples, complete similarity metrics were calculated and 
clustering was performed using Euclidean distance and average linkage. Mann Whitney 
test was performed with Benjamini Hochberg FDR. Differences in miRNAs were considered 
statistically significant if the P value was less than 0.05. To identify biologically relevant 
miRNAs a fold change in expression level of at least 4.0 was taken as a cut off.86
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Results
76 miRNAs were >four fold differentially expressed between the four NHL subtypes (Table 
1). Unsupervised clustering of these miRNAs demonstrated an inversed pattern for BL and 
CLL. The pattern for FL and MCL was similar but less distinctive as compared to the BL and 
CLL (Fig. 1). The highest numbers of differentially expressed miRNAs were observed between 
BL and the other three NHL, i.e. 52 with CLL, 32 with MCL and 30 with FL. In contrast only 
five to eight miRNAs were significantly differently expressed in comparisons between MCL, 
FL and CLL. Analysis of a predictor subset for BL vs CLL reported by Zhang et al 1, revealed 
that 11 of the 20 miRNAs were evaluable in our NHL samples (the other 9 were not flagged 
as present). Unsupervised clustering of these miRNAs in the presently studied cases of BL 
and CLL revealed a distinct clustering pattern discriminating between BL and CLL (Figure 2). MiRNA profiling in B cell non-Hodgkin lymphoma:   
a MYC-related miRNA profile characterizes Burkitt lymphoma
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Table 1. Overview of the 76 miRNAs differentially expressed in the four NHL
Fold MCL FL CLL
BL
up >16 miR-629, miR-663
8-16 miR-560,  miR-629, miR-663 miR-629, miR-663 miR-18a,  miR-560
4-8 miR-18a*, miR-136, miR-
373*, miR-376a, miR-492, 
miR-498, miR-557,  miR-584
miR-17, miR-18a,  miR-
18a*, miR-19a, miR-20a, 
miR-20b, miR-373*, miR-
557, miR-560
miR-181a, miR-181a*,   
miR-181b, miR-182,  miR-
188, miR-193b,  miR-373*, 
miR-452, miR-492, miR-498,     
miR-513, miR-557, miR-584, 
miR-601, miR-630
down 4-8 let-7B, let-7G, miR-10b, 
miR-26a, miR-29a, miR-139, 
miR-195, miR-29b,  miR-
30e-5p, miR-196a, miR-455, 
miR-497
miR-26a, miR-29a,  miR-31, 
miR-29b, miR-99b, miR-
125a, miR-139,   miR-146a,  
miR-155,  miR-196b, miR-
222, miR-455, miR-497,  
miR-768-3p,  miR-768-5p
let-7C, let-7C, let-7E, let-7F, 
miR-7a, miR-15a, miR-26b, 
miR-99a,  miR-142-3p,  miR-
195, miR-196a,  miR-200c,  
miR-221,  miR-222, miR-
223,  miR-335, miR-338, 
miR-361, miR-660
8-16 miR-29c, miR-146a, miR-
338, miR-363, miR-768-3p, 
miR-768-5p
miR-29c, miR-138,  miR-582 let-7G, miR-10b,  miR-26a,  
miR-29a, miR-30e-5p,  
miR-101, miR-139, miR-497, 
miR-768-3p
>16 miR-14, miR-150, miR-200c miR-150 miR-29c, miR-150,  miR-
155,  miR- 768-5p
FL
up >16
8-16 miR-182
4-8 miR-136, miR-582 miR-138,  miR-582
down 4-8 miR-101,  miR-150,  miR-
335
8-16 miR-363
>16 miR-141,  miR-200c
CLL
up >16 miR-335
8-16
4-8 miR-150, miR-155
down 4-8 miR-181c, miR-200c, miR-
363
8-16 miR-141
>16 miR-182
Five of the miRNAs, i.e. miRNAs, i.e. miR-146a, miR-150, miR-193b, miR-221 and miR-222, differentially 
expressed between the four B cell lymphoma subtypes are also differentially expressed between the 
four normal B cell subsets (Supplementary file 1). 88
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Figure 1. Heatmap generated by unsupervised hierarchical clustering of the 76 miRNAs differentially 
expressed between MCL, BL, FL and CLL. Most distinct inverse patterns are observed for BL and CLL. 
FL and MCL display a less specific, intermediate expression pattern. 
 ﾠMiRNA profiling in B cell non-Hodgkin lymphoma:   
a MYC-related miRNA profile characterizes Burkitt lymphoma
89
Figure 2. Comparison of our profiling data with the previously published predictor miRNA set of 
Zhang et al., (2009). Since the total data set is not available yet we only show the heatmap for the 
miRNAs specifically mentioned in the paper of Zhang et al. The heatmap contains 11 out of the 20 
miRNA predictor set reported by Zhang et al separating BL from CLL. The other nine miRNAs were not 
flagged as present. The Heatmap indicates that BL and CLL can be separated based on the predictor 
set of Zhang et al.
 ﾠ90
Chapter 4
References
1.   Zhang,J.,  Jima,D.D.,  Jacobs,C.,  Fischer,R.,  Gottwein,E.,  Huang,G.,  Lugar,P.L.,  Lagoo,A.S., 
Rizzieri,D.A., Friedman,D.R., Weinberg,J.B., Lipsky,P.E., & Dave,S.S. (2009) Patterns of microRNA 
expression characterize stages of human B cell differentiation. Blood 113, 4586-4594MiRNA profiling in B cell non-Hodgkin lymphoma:   
a MYC-related miRNA profile characterizes Burkitt lymphoma
91
Figure S1. Heatmap of the miRNAs differentially expressed (> 4 fold) between the lymphomas and 
their postulated normal counterparts. A, Heatmap of the 77 miRNAs differentially expressed between 
MCL and naïve B cells. B, Heatmap of the 69 miRNAs differentially expressed between FL and GC B 
cells. C, Heatmap of the 54 differentially expressed miRNAs between BL and GC B cells. D, Heatmap of 
the 70 miRNAs differentially expressed between CLL and memory B cells. 
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Table S1. Overview of known c-Myc regulated miRNAs and differential expression between BL versus 
CLL, MCL and FL.
c-Myc Regulated miRNAs Significant differences between BL
 and other NHL  
induced
miRNA species ref BS flagged  p-value corrected p-value regulation fold change
miR-7 HSA & MMU 3   yes 0.0264 0.0340 up 2
miR-17-3p HSA 3 yes yes ns
miR-17-5p HSA & MMU 1,2,3,4 yes yes 0.0264 0.0340 up 2
miR-18a HSA & MMU 1,4 yes yes 0.0004 0.0011 up 4
miR-19a HSA 1,3 yes yes 0.0138 0.0188 up 3
miR-19b HSA & MMU 1,4 yes yes ns
miR-20a HSA & MMU 1,3,4 yes yes 0.0298 0.0375 up 2
miR-20b HSA 3 yes ns
miR-92 HSA & MMU 1,3,4 yes yes ns
miR-106a HSA & MMU 3,4 yes 0.0105 0.0161 up 2
miR-128b HSA 3 yes ns
miR-130b MMU 4 yes 0.0038 0.0064 up 3
miR-206 MMU 3 yes ns
miR-213 HSA 3 no
miR-370 MMU 3 yes 0.0138 0.0188 up 2
miR-422a HSA 3 no
miR-468 MMU 3 no
Repressed
miRNA
let-7e HSA 3   yes 0.0002 0.0010 down 4
miR-15a HSA & MMU 3 yes 0.0038 0.0064 down 3
miR-16 HSA & MMU 3,4 yes 0.0017 0.0035 down 2
miR-22 HSA & MMU 3 yes 0.0138 0.0188 down 2
miR-23a HSA 3,5 yes 0.0005 0.0013 down 2
miR-23b HSA 5 yes 0.0038 0.0064 down 2
miR-24 HSA 3 yes 0.0002 0.0010 down 3
miR-26a HSA & MMU 3,4 yes 0.0002 0.0010 down 7
miR-26b HSA 3 yes 0.0002 0.0010 down 4
miR-29a HSA & MMU 3 yes yes 0.0002 0.0010 down 9
miR-29b HSA 3 yes yes 0.0002 0.0010 down 8
miR-29c HSA & MMU 3 yes yes 0.0002 0.0010 down 16
miR-30c HSA 3 yes 0.0059 0.0094 down 2
miR-30e-3p HSA 3 yes 0.0051 0.0083 down 3
miR-30e-5p HSA 3 yes 0.0002 0.0010 down 6
miR-34a HSA & MMU 3 yes yes 0.0006 0.0015 down 2
miR-99b HSA 3 yes 0.0014 0.0031 down 3
miR-101a MMU 3 yes 0.0003 0.0010 down 6
miR-125b HSA 3 no yes 0.0004 0.0012 down 2
miR-134 MMU 4 no
miR-139 MMU 3 yes 0.0004 0.0011 down 7
miR-140 MMU 3 yes 0.0121 0.0179 down 3
miR-142-3p MMU 3 yes 0.0032 0.0061 down 4
miR-144 MMU 3 yes ns
miR-146a HSA & MMU 3 yes yes 0.0004 0.0012 down 5
miR-150 HSA & MMU 3 no yes 0.0002 0.0010 down 45
miR-195 HSA & MMU 3 yes yes 0.0002 0.0010 down 5
miR-207 MMU 4 no
miR-210 HSA 3 yes ns
miR-215 MMU 3 yes ns
miR-223 HSA 3 yes 0.0009 0.0020 down 4
miR-342 MMU 3 yes 0.0002 0.0010 down 3
miR-451 HSA 3 yes ns
miR-466 MMU 3 no
miR-467 MMU 3 no
miR-489 MMU 4 no
miR-494 MMU 4 yes 0.0020 0.0039 up 3
let-7a HSA 2 yes 0.0002 0.0010 down 3
miR-124 HSA 2 no
miR-148 HSA 2 yes ns
miR-155 HSA 2 yes 0.0003 0.0010 down 8
miR-196 HSA 2 yes 0.0012 0.0027 down 4
miR-346 HSA 2 noMiRNA profiling in B cell non-Hodgkin lymphoma:   
a MYC-related miRNA profile characterizes Burkitt lymphoma
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Table SII. Overview of validated target genes for differentially expressed miRNAs
miRNA Target genes References 
hsa-let-7b BCL7A, CDC25A, CyclinD1, -D3, - A, Cdk4, 
HMGA2, MTPN
Huang et al, 2007, Wang et al, 2007, 
Sampson et al, 2007, 
Schultz et al, 2008, Motoyama et al, 2008 
hsa-miR-7  EGFR, IRS-2 Kefas et al, 2008
hsa-miR-10b HOXA10, HOXD10, RHOC, MEIS1 Ma et al, 2007, Garzon et al, 2008
hsa-miR-15a BCL2, CCND1, WNT3A Cimmino et al, 2005, Bonci et al, 2008
hsa-miR-15b  BCL2 Xia et al, 2008
hsa-miR-18a GR, CCN2, ESR1 Uchida et al, 2008, Ohgawara et al, 2009, Liu 
et al, 2009
hsa-miR-17-5p  BCL2L11/BIM, E2F1-3, PTEN, 
CDKN1A/p21, RBL2
O’Donnell et al, 2005, Novotny et al, 2007, 
Wang et al, 2007, 
Ivanovska et al, 2008, Xiao et al, 2008
hsa-miR-23a/b Glutaminase Gao et al, 2009
hsa-miR-26a EZH2, SMAD1 Sander et al, 2008, Wong et al, 2008, Luzi et 
al, 2008
hsa-miR-29a BACE1, CDC42, NEF, p85α  Hariharan et al, 2005, Hebert et al, 2008, He 
et al,  2008, 
Park et al, 2009, Ahluwalia et al 2008
hsa-miR-29b CDC42 Mcl-1, NEF, p85α Hariharan et al, 2005, Mott et al, 2007, Park 
et al, 2009
hsa-miR-29c CDC42, p85 α Park et al, 2009
hsa-miR-93  E2F1, CDKN1A/p21 Petrocca et al, 2008, Mendell et al, 2008
hsa-miR-101 ATXN-, COX-2, EZH2 Lee et al, 2008, Strillacci, 2009, Friedman 
2009
hsa-miR-106a  RB1, IL10 Volinia et al, 2006, Sharma et al, 2009
hsa-miR-125b IRF4, PRDM1/BLIMP1 Malumbres et al, 2009
hsa-miR-130b  MECP2 Burmistrova et al,  2007
hsa-miR-138 h-TERT Mitomo et al, 2008
hsa-miR-141 ATGF beta2, EMT, E-Cadherin, SIP1,
 ZEB1, ZFHX1B, ZEB2
Katoh et al, 2008, Nakada et al, 2008
hsa-miR-146a BRCA-1, BRACA-2, CXCR4, IRAK-1, 
IFNγ, iNOS, LMP-1, NFκB, PTC1, ROCK1, 
TRAF6 
Taganov et al, 2006, Labbaye et al, 2008, Dai 
et al, 2008
hsa-miR-148a  DNMT3b, TGIF2 Duursma et al, 2008, Lujambio et al, 2008
hsa-miR-150  MYB, P2X7 Zhou et al, 2008, Lu et al, 2008, Xiao et al, 
2008, Barroga et al, 2008
hsa-miR-155 AID, RhoA, AGTR1, FGF7, ZNF537, ZIC3, 
IκBκε, AGTR1, BACH1, Fos, Pu.1, 
TP53INP1
Kong et al, 2008, Gibcus et al, 2009, Gottwein 
et al, 2007, 
Tili et al, 2007, Yin et al, 2008, Vigorito et al, 
2007, Gironella et al, 2007
hsa-miR-181c PCAF  Liu et al, 2007
hsa-miR-182 ADCY6, JAK2  Guqlielmelli et al, 2007, Xu et al, 2007
hsa-miR-195 NGN3, NeuroD, NKX2 Joqlekar et al, 2007, Mellios et al, 2008
hsa-miR-196a ANXA1, HOX, HOXb8 Mansfield et al, 2004, Debernardi et al, 2007, 
Luthra et al, 2008, 
Kim et al 2009 
hsa-miR-196b HOXB8a Cohen et al, 2008
hsa-miR-200c E-cadherin, ZEB1, ZEB2, TGFβ2 Hurteau et al, 2006 -2007,  Burk et al, 2008, 
Nakada et al, 2008, 
Park et al, 2008 94
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miRNA Target genes References 
hsa-miR-221  HOXB5, ERα, CDKN1B/p27, c-Kit, 
CDKN1C/p57
Visione et al, 2007, Kim et al,  2008, Zhao et 
al,  2008, 
Miller et al, 2008, Fornari et al,  2008
hsa-miR-222 Era, MYC, CDKN1B/p27, c-KIT, p57 Fell et al,i 2005, Poliseno et al, 2006, Visione 
et al, 2007,
 Zhao et al, 2008, Sun et al,  2008, Miller et 
al, 2008, Urbich et al, 2008, 
Felicetti et al, 2008, Medina et al, 2008  
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Abstract
MYC is an oncogenic transcription factor involved in multiple cellular processes by regulating 
the expression of more than 50 microRNAs (miRNAs). Several studies showed that MYC 
contributes to the miRNA expression profile of B-cell non-Hodgkin lymphoma (NHL). In this 
study we analyzed the functional role of 11 miRNAs differentially expressed between MYC-
high Burkitt lymphoma (BL) and MYC-low chronic lymphocytic leukemia (CLL) as determined 
in our previous miRNA profiling (Robertus et al, 2010). Differential expression was confirmed 
on the same patient set as used for the original microarray study and on a new patient 
cohort. Overexpression of the ten MYC-repressed miRNAs in ST486 BL cells revealed for 6 
miRNAs a more than 50% decrease in the percentage of green fluorescent protein (GFP)+ 
cells  in  a  period  of  18  days  indicating  tumor  suppressive  activity.  One  MYC  repressed 
miRNA, i.e. miR-155, induced a more than 50% increase in GFP+ cells upon overexpression 
indicating a growth advantage. Inhibition of the miR-17~92 cluster, including the only MYC-
induced miRNA, miR-18, revealed no significant effect on cell growth. Our findings show 
that overexpression of only one of the high number of known MYC regulated miRNAs, is 
sufficient to induce a marked effect on cell growth. 
 
CLL casesMYC regulated miRNAs play a role in the high proliferative state of Burkitt lymphoma cells
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Abstract
MYC is an oncogenic transcription factor involved in multiple cellular processes by regulating 
the expression of more than 50 microRNAs (miRNAs). Several studies showed that MYC 
contributes to the miRNA expression profile of B-cell non-Hodgkin lymphoma (NHL). In this 
study we analyzed the functional role of 11 miRNAs differentially expressed between MYC-
high Burkitt lymphoma (BL) and MYC-low chronic lymphocytic leukemia (CLL) as determined 
in our previous miRNA profiling (Robertus et al, 2010). Differential expression was confirmed 
on the same patient set as used for the original microarray study and on a new patient 
cohort. Overexpression of the ten MYC-repressed miRNAs in ST486 BL cells revealed for 6 
miRNAs a more than 50% decrease in the percentage of green fluorescent protein (GFP)+ 
cells  in  a  period  of  18  days  indicating  tumor  suppressive  activity.  One  MYC  repressed 
miRNA, i.e. miR-155, induced a more than 50% increase in GFP+ cells upon overexpression 
indicating a growth advantage. Inhibition of the miR-17~92 cluster, including the only MYC-
induced miRNA, miR-18, revealed no significant effect on cell growth. Our findings show 
that overexpression of only one of the high number of known MYC regulated miRNAs, is 
sufficient to induce a marked effect on cell growth. 
 
CLL cases
Introduction
B-cell  non-Hodgkin  lymphoma  (NHL)  accounts  for  approximately  90%  of  all  lymphoid 
malignancies, with an annual incidence of approximately 19 cases per 100,000 individuals 
1.  Burkitt  lymphoma  (BL)  represents  approximately  1-2%  of  all  lymphoma  cases  and 
most frequently affects young children  2. It is a homogeneous, fast growing lymphoma 
subtype, characterized by a chromosomal translocation between the MYC gene and one 
of the immunoglobulin heavy or light chain gene regions. These translocations result in 
overexpression of MYC 3 and a biological and pathological behavior that is consistent with a 
MYC driven proliferation of germinal center derived B cells 3.
MYC  is  an  oncogenic  transcription  factor  involved  in  cell  growth,  proliferation 
and maintenance of stem cell properties 4, 5. The importance of MYC action was recently 
underlined by the identification of approximately 7,000 MYC binding sites in BL cell lines 
6-8. Besides regulation of a high number of protein-coding genes, MYC also regulates the 
expression of multiple microRNAs (miRNAs). MiRNAs are short (21-23 nucleotides) non-
coding RNA molecules that mediate posttranscriptional silencing of their target genes  9. 
MiRNAs participate in many important cellular processes like cell cycle regulation, apoptosis 
and proliferation  10, 11 and deregulated miRNA expression has been observed in various 
lymphomas 12. There are approximately 60 know MYC regulated miRNAs of which the vast 
majority is repressed by MYC. A small subset, including the oncogenic miR-17~92 cluster 
are induced by MYC 13, 14. Two members of this cluster, miR-19a and miR-19b, have been 
identified as the main contributors of tumorigenesis in a B cell lymphoma mouse model 15, 16. 
Two other members of the miR-17-92 cluster, i.e. miR-17 and miR-20a, have been shown to 
target E2F1, a pro apoptotic member of the E2F family 14. E2F1 itself is also a target of MYC 
suggesting a regulatory feedback loop 14. 
In a previous study 18, we identified a clear MYC induced miRNA expression profile 
in BL as compared to MYC low lymphoma including chronic lymphocytic leukemia (CLL), 
mantle cell lymphoma and follicular lymphoma. In this study we further examined the role 
of 11 MYC regulated miRNAs in BL cells, including one up- and ten downregulated miRNAs.104
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Materials and Methods
Tissue samples 
Germinal center (GC) (IgD-CD38+) B cells were purified from 3 human tonsils obtained from 
children undergoing routine tonsillectomy as previously described 18. Specimens of frozen 
lymph nodes of 6 BL and 12 CLL patients used in the previous miRNA profiling study 18 were 
used to confirm the differential expression patterns of 11 selected miRNAs (see below). 
For the independent validation set, paraffin embedded patient material was used of 7 
additional BL cases and 15 additional CLL cases. Each individual diagnosis was reviewed 
by an experienced hematopathologist according to the classification of the 2008 WHO 19. 
The BL samples were derived from pediatric patients with an abdominal mass (phenotype: 
CD10+, BCL2-, EBV- and MYC/8q24 breakpoint positive as assessed by fluorescence in situ 
hybridization).  The  CLL  samples  were  retrieved  from  patients  with  nodal  presentation 
(phenotype: CD5+, CD23+, cyclinD1-). All protocols for obtaining human tissue samples were 
performed in accordance to the guidelines from the Institutional review board or Medical 
Ethical committee of the University Medical Center Groningen.
Cell lines
The ST486 cell line was cultured at 37ºC under an atmosphere containing 5% CO2 in RPMI-
1640 medium (Cambrex Biosciences, Walkersville, USA) supplemented with ultraglutamine 
(2mM), penicillin (100U/ml), streptomycin (0.1mg/ml; Cambrex Biosciences), and 20% fetal 
calf serum (Cambrex Biosciences). ST486 was purchased from ATCC. Phoenix-ampho cells 
were cultured in DMEM supplemented with 2mM ultraglutamine, 100 U/ml penicillin/
streptomycin and 10% fetal bovine serum (Cambrex Biosciences).
miRNA and miRNA sponge overexpression 
MiRNAs were cloned as previously described 20. Briefly, primers with 5’ Xho1 and 3’ EcoR1 
restriction sites were designed to amplify the miRNA precursor and flanking sequence 
(Supplementary Table 1). MiRNA genes were amplified from DNA of a healthy control 
and cloned into the retroviral vector MXW-PGK-IRES-GFP. The miR-17~92 sponges were 
generated previously 21. 
Retroviral transductions
To generate retroviral particles, Phoenix-Ampho packaging cells were CaPO4 transfected 
using 37,5μg retroviral vector in T75 flasks. Viral particles were harvested after two days MYC regulated miRNAs play a role in the high proliferative state of Burkitt lymphoma cells
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and  concentrated  with  Retro-X  concentrator  (Clontech,  Saint-Germain-en-Laye,  France) 
according to the manufacturer’s protocol. Target cells were transduced with the virus by 
spinning at 2,000rpm for 2hrs with a final polybrene concentration of 4µg/ml. 
GFP competition assay
After infection of ST486 cells, GFP expression was monitored tri-weekly for a period of three 
weeks. Data were acquired on a FACS Calibur flow cytometer (BD PharMingen) and analyzed 
using FlowJo software (version 7.6, Treestar, Ashland, OR). The GFP percentage determined 
at the first day of measurement (3 days post infection) was set to 1. Each GFP competition 
assay was performed at least twice. GFP+ cells were sorted ~2 weeks after infection using 
a MoFlo sorter (Dako cytomation) to monitor the induction of the overexpressed miRNA.
RNA isolation procedure and quality check 
Total  RNA was  isolated  from the purified B cell subsets, frozen tissue samples and GFP 
sorted cells using  Trizol  (Invitrogen,  Carlsbad,  CA, USA)  according  to  the  manufacturer’s 
protocol. The integrity of the RNA was checked on a 1% agarose gel. Only good quality RNA 
samples were used for subsequent analysis. RNA from FFPE tissue was extracted as reported 
previously by Specht et al 60. Samples were DNAse treated using Turbo DNA free kit (Ambion, 
USA) according to the manufacturer’s instructions. Efficiency of the DNase procedure was 
checked using a multiplex PCR with 5 primer sets specific for different genomic DNA loci 
and subsequent analysis on a 1.5% agarose gel. No PCR products were seen confirming the 
effectiveness of the DNAse treatment. RNA concentrations were measured on a NanoDrop® 
ND-1000 Spectrophotometer (Nano Drop Technologies, Wilmington, Delaware, USA).
Quantitative (q)RT-PCR  
For miRNA-specific cDNA synthesis we used 5ng total RNA, the Taqman MicroRNA Reverse 
Transcription Kit and Taqman miRNA assays (let-7a, miR-18a, miR-26a, miR-26b, miR-29a, 
miR-29b, miR-29c, miR-101, miR-142, miR-150, miR-155). The qPCR reaction was carried out 
on 0.44ng cDNA using miRNA specific primers in accordance with the instructions supplied 
by the manufacturer (Applied Biosystems, Foster City, CA, USA). RNU49 was selected as a 
housekeeping gene to normalize the miRNA levels as it showed the most uniform expression 
level in all samples and appropriate threshold Ct values. 
To determine the MYC transcript levels, qRT-PCR was performed using a Taqman 
gene expression assay (Hs00153408, Applied Biosystems, Foster City, CA, USA) according 
to the instructions of the manufacturer. Random hexamers were used to prime the cDNA 106
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synthesis using 300ng of total RNA and Superscript II (First-Strand cDNA Synthesis System, 
Invitrogen, Carlsbad, CA, USA). The PCR reactions were performed in triplicate in a volume 
of 20 µl with 1× qPCR master mix (Eurogentec, Liège, Belgium) and 2ng cDNA. For frozen 
patient material the MYC expression levels were normalized to RPII for RNA isolated from 
frozen tissue and to U6 for RNA isolated from paraffin embedded material. 
All reactions were performed on an ABI7900HT Sequence Detection System device 
(Applied Biosystems) using the standard program (10 min at 95°C, followed by 40 cycles 
of 15s at 95°C and 60s at 55°C). Relative expression levels were calculated using the delta 
Ct method [∆Ct= Ct(gene of interest) - Ct(housekeeping gene)]. The standard deviation 
(SD) of the ∆Ct [SD(Ct)] was calculated using the formula [SD(∆Ct)=SD(gene of interest)2 + 
SD(housekeeping gene)2]. The factor difference was calculated as 2-∆Ct. 
Statistical analysis
Selection of significant differential expressed miRNAs between BL and CLL samples was 
determined using a Kruskal-Wallis test with Bonferroni multiple testing correction using 
Genespring GX 12.0 software (Agilent, Santa Clara, CA) and a fold difference cut-off of four. 
Unsupervised clustering analysis of the 11 resulting miRNAs was performed using Genesis 
(Sturn et al., 2002). After median centering of the miRNA expression data over all samples, 
complete similarity metrics were calculated and clustering was performed using Euclidean 
distance and average linkage. 
Significant differences in the expression levels within the qRT-PCR data of the array 
cases including the GC B cells, was established with a Mann-Whitney test and a Dunn’s 
multiple comparisons as a post-test. The qRT-PCR data of the validation cases were analyzed 
with a Kruskal-Wallis test (Prism 6.0, GraphPad Software Inc., San Diego, CA). P values of less 
than 0.05 were considered statistically significant. 
Validated target genes search
A list of validated target genes was compiled utilizing miRecords 22 (release date November 
25, 2010) and an extensive literature search identifying published experimentally validated 
candidate miRNA target genes. Validation was defined as downregulation in a luciferase 
reporter assay, or downregulation at the protein level shown by Western blot or FACS.MYC regulated miRNAs play a role in the high proliferative state of Burkitt lymphoma cells
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Results
Selection of MYC regulated miRNAs
Selection of MYC regulated miRNAs was based on our previously published miRNA profiling 
study of NHL 18. We focused specifically on the comparison between BL and CLL, since these 
two NHL subtypes showed the most extreme differences of the MYC regulated miRNAs. Ten 
of the 11 selected miRNAs showed a significant higher expression level in BL with differences 
in expression ranging from 4.3 to 95 fold. One miRNA, i.e. miR-18a, showed a higher level 
(4 fold) in BL compared to CLL. The germinal center B cells (GCB) showed an intermediate 
expression pattern for the ten MYC repressed miRNAs whereas the level of the MYC induced 
miR-18a in GC B cells was similar to the level observed in BL cases (Fig. 1).
Fig. 1. Heatmap of the 11 miRNAs selected for functional studies. Heatmap of 11 miRNAs in six BL and 
12 CLL samples and three GCB cell subsets of the microarray profiling data of our previous profiling 
study (Robertus et al., 2010) 24. Unsupervised clustering shows a clear distinction between BL and CLL, 
with the GCB cells clustering together with the CLL cases. 
qRT-PCR validation of candidate miRNAs
To validate the expression levels of the eleven miRNAs, qRT-PCR was performed using the 
same cases as used for the miRNA expression profiling study 18 (Fig. 2A). As expected, MYC 
levels were significantly higher in BL compared to CLL cases. Eight out of ten MYC repressed 
miRNAs  showed  significant  differences  in  expression  between  BL  and  CLL.  MiR-142-3p 
CLL cases  BL cases  GC 108
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and Let-7a also showed the expected trend but differences were not significant. MiR-18a 
showed significantly higher expression levels in BL compared to CLL. 
In a second independent patient cohort consisting of 7 BL and 15 CLL cases. MYC 
levels were also significantly higher in BL compared to CLL cases. A significantly lower 
expression was observed of all ten MYC-repressed miRNAs and significantly increased levels 
of miR-18a in BL cases compared to CLL cases (Fig. 2B). Thus, differential expression of all 
MYC regulated miRNAs showed the expected expression pattern in MYC-high BL compared 
to MYC-low CLL.
Fig. 2. Validation of differentially expression patterns of the 11 selected miRNAs. A. Nine 
of the selected miRNAs showed a significant difference of expression between the MYC-
high BL cases and the MYC-low CLL cases used for the profiling study. The MYC repressed 
miR-18a showed a significant higher expression in BL compared to CLL. MYC levels were 
significantly higher expressed in BL compared to CLL.  B. Seven independent BL cases and 
15 independent CLL cases showed significantly different miRNA expression levels between 
BL cases and CLL cases for all 11 miRNAs. MYC levels were significantly higher expressed in 
BL compared to CLL. 
MYC regulated miRNAs affect BL cell growth
To  determine  the  effect  of  the  MYC  repressed  miRNAs,  we  stably  overexpressed  the 
ten  selected  MYC  repressed  miRNAs  in  the  EBV  negative  BL-derived  cell  line  ST486. 
Overexpression of the miRNAs was validated on RNA isolated from FACS sorted GFP positive 
A  B MYC regulated miRNAs play a role in the high proliferative state of Burkitt lymphoma cells
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cells. Of the ten miRNAs analyzed for overexpression, miR-150, miR-26a/b, miR-29a, let-7a 
and miR-155 showed overexpression ranging from 8 to 3000 fold (Fig. 3a). MiR-29c showed 
only a slight overexpression compared to empty vector control and no overexpression was 
observed for miR-29b, miR-101 and miR-142-3p. It should be noted that the endogenous 
Ct values were very low for miR-142-3p, which might make it difficult to further enhance 
expression of this miRNA. 
Next,  we  determined  the  effect  of  overexpression  of  the  ten  MYC  repressed 
miRNAs on growth of ST486 cells in a GFP competition assay (Fig. 3b). For six miRNAs the 
GFP percentage decreased more than 50% within 3 weeks. For miR-150 a 50% reduction in 
GFP+ cells took less then 2 days, for miR-26a and miR-26b ~6 days and for miR-29a, miR-29b 
A 
B 
Fig 3. Overexpression and effect on growth of the 10 MYC repressed miRNAs. A. Quantification of 
overexpression by qRT-PCR of the ten MYC repressed miRNAs in the BL ST486 cell revealed a clear 
induction with fold changes ranging from 8 to 3,000 as compared to wild type and empty vector. B. 
GFP competition assay in ST486 cells for the ten MYC repressed miRNAs. The empty vector control 
showed a consistent percentage of GFP+ cells, as expected. Six miRNAs showed a more than 50% 
decrease in GFP+ cells, whereas one miRNA, miR-155 showed more than 80% increase in GFP+ ST486 
cells. Two miRNAs showed no effect on proliferation and one miRNA, let-7a showed a minor decrease 
in GFP+ cells.110
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and miR-101 ~14 days. Let-7a showed a slight decrease of 20% in GFP+ cells in 3 weeks. MiR-
155 was the only miRNA that showed an increase in GFP+ cells over time with a more than 
80% increase in GFP+ cells in three weeks. MiR-142 and miR-29c showed no clear changes in 
the percentage of GFP+ cells as was the case for the empty vector control. Thus, seven out 
of ten MYC repressed miRNAs affected the growth of ST486 cells, six miRNAs decreased cell 
growth and one miRNA increased cell growth.
miR-17~92 inhibition only moderately affects cell growth
Our microarray data indicated that besides in addition to miR-18, also the other members 
of the miR-17~92 cluster showed higher expression levels in BL compared to CLL. This did 
not reach significance, probably due to large differences between individual samples (Fig. 
4A). Therefore, we decided to determine the effect of inhibition of the entire miR-17~92 
cluster on BL cell growth. To this end we used previously generated miRNA sponges that 
contain three binding sites for each miRNA seed family member present in the miR-17~92 
cluster 23. Overexpression of two miR-17~92 sponges that differ in the order of the miRNA 
binding sites and in the spacer sequences between the binding sites resulted in a consistent 
minor decrease in cell growth (~20% decrease in percentage of GFP+ cells). The empty 
vector control and the control with scrambled miRNA seed binding regions did not show 
any decrease in the percentage of GFP+ cells (Fig. 4b). 
Experimentally validated target genes of the miRNA showing a phenotype
A list of validated target genes was compiled for the seven miRNAs that showed an effect 
on ST486 cell proliferation using miRecords in combination with a literature search. The 
resulting target gene list is shown in Supplementary table 2. This search revealed 8 targets 
for miR-26a, 5 targets for miR-26b, 14 targets for miR-29a, 19 targets for miR-29b, 24 target 
for miR-101, 12 targets for miR-150 and 173 targets for miR-155.
Based on a more than 50% change in GFP+ cells, miR-150, miR-26a/b and  miR-
155  were  selected  as  the  potentially  most  interesting  miRNAs.  Target  genes  of  these 
four miRNAs with potential interest to B cell lymphoma, proliferation or tumorigenesis, 
included amongst others; Apoptotic BCL2-asscociated athanogen 4 (BAG4), Pleiomorphic 
adenoma gene 1 (PLAG1), Phosphatase and tensin homologue (PTEN), Enhancer of zeste 
homolog 2 (EZH2) and transcription factor E2F7 (E2F7) for miR-26a/b; c-myb, Fms-like 
tyrosine kinase 3 (FLT3), Early growth response 2 (EGR2), Mucin 4, cell surface associated 
(MUC4), V-AKT murine thymoma viral oncogene homolog 2 (AKT2), Dyskeratosis congeita 
1 (DKC1), Purinergic receptor P2X, Ligand-gated ion channel (P2RX7) and Zinc finger E-box 
binding homeobox 1 (ZEB1) for miR-150; and Tumor protein p53-inducible nuclear protein MYC regulated miRNAs play a role in the high proliferative state of Burkitt lymphoma cells
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1 (Tp53INP1), Histione deacetylase 4 (HDAC4), Transforming growth factor beta regulator 1 
(TBRG1) and Phosphatidylinositol, 3-kinase regulatory subunit alpha (PIK3R1) for miR-155.
Fig 4. Inhibition of miR-17~92 in ST486 cells. A. Expression levels of all members of the miR-17~92 
cluster based on the profiling data. Each miRNA showed a higher level of expression in BL cases 
compared to CLL cases, but the difference was significant only for miR-18a. B. GFP competition assay 
in ST486 cells infected with the combi-sponges against the miR-17~92 cluster. Simultaneous inhibition 
of the entire miR-17~92 cluster and other seed family members resulted in a 20% decrease in GFP+ 
cells. An empty vector and a combi-sponge vector with seed scrambled miRNA binding sites were used 
as negative controls.
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Discussion
In  recent  studies  MYC  has  been  shown  to  play  an  important  role  in  influencing  the 
expression pattern of miRNAs in B-cell NHL. In this study we showed a functional effect of 7 
MYC repressed miRNAs. Six miRNAs repressed ST486 cell growth and one miRNA enhanced 
ST486 cell growth. 
MYC repressed miRNAs miR-150, miR-26a/b, miR-29a and miR-155 showed a clear 
overexpression in sorted GFP+ cells and also showed a clear effect on cell growth. Let-7a 
showed overexpression but no clear effect on cell growth. MiR-101 and miR-29b showed 
no overexpression but did show a negative effect on cell growth. As the Ct values for miR-
101 and miR-29b were high it might be that the lack of detectable overexpression is caused 
by ineffective miRNA production of the construct or production of miR-101 isoforms that 
cannot be detected by the miR-101 assay. The latter explanation might be more likely for 
these two miRNAs given their effect on ST486 cell growth. MiR-142-3p and miR-29c showed 
no clear overexpression and also no change in cell growth. Thus no conclusions can be 
drawn for these two miRNAs. For miR-142-3p the endogenous levels are already very high 
and it is very well possible that miR-142-3p needs to be repressed in order to evaluate any 
possible effect on cell proliferation. For three of the ten miRNAs i.e. miR-26b, miR-29c and 
miR-142-3p, qRT-PCR assays were used that target a miRNA isoform that is according to the 
miRBASE 62 not the most abundant isoform. 
The  MYC-induced  miRNA,  miR-18a,  showed  higher  expression  levels  in  BL  as 
compared to CLL. In addition, higher expression was also observed for the other members 
of the miR-17-92 cluster. Overexpression of sponge constructs containing all six members 
of the miR-17~92 clusters showed a ~20% decrease in ST486 cell growth. It has been shown 
that the miR-17~92 cluster can cooperate with MYC in mouse models of MYC induced B-cell 
lymphomagenesis. In particular miR-19 was shown to be critically involved 6, 7. Although we 
observed a specific consistent minor effect with both miR-17~92 sponges it is at present 
unclear whether this effect is the maximal influence of the miR-17~92 cluster on BL cell 
growth whether this limited effect is due to incomplete inhibition of the highly expressed 
miR-17~92 cluster. 
Of the six miRNAs that induced a clear decrease in ST486 cell proliferation, the miR-
150 effect was most prominent. This is consistent with previous data 24, 25 showing that miR-
150 has tumor suppressive activity in a mouse model using MYC transduced B cell lymphoma 
cell lines and in NK and NK/T-cell lymphoma lines. MiR-150 has 12 experimentally validated 
target genes, including 8 genes related to cell growth, lymphoma or tumorigenesis. One of 
these target genes is c-Myb. C-Myb is a known proto-oncogene with elevated expression MYC regulated miRNAs play a role in the high proliferative state of Burkitt lymphoma cells
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levels in acute myeloid and lymphoid leukemia  17, 26. Knock down of miR-150 and c-Myb 
both have a pronounced affect on B-cell differentiation, indicating that c-Myb is a main 
target in defining the miR-150 phenotype 27. Moreover, we recently showed an inversed 
correlation between miRNA-150 and c-Myb protein expression on normal tonsils  28. In 
human  B-cell  leukemia  lines,  knockdown  of  c-Myb  expression  suppressed  proliferation 
and colony formation. In AML, miR-150 functions as a tumor suppressor by repression of 
FLT3 and c-Myb. Both genes are involved in the HOXA9/MEIS1/FLT3/Myb/Lin28 signaling 
network 29. Moreover, MYC is a known target of c-Myb 30 suggesting a possible feedback 
loop with miR-150. Another validated miR-150 target is early growth response 2  (EGR2) 31. 
This zinc-finger transcription factor is a member of the early growth response gene (EGR) 
family. EGR2 is a pro apoptotic gene and plays a role in B cell development 32 and is also 
involved in the development of T and B cells 33. Mucin 4, cell surface associated (MUC4) 
suppresses growth and malignant behavior of pancreatic cancer cells  34. V-AKT murine 
thymoma  viral  oncogene  homolog  2  (AKT2)  is  overexpressed  in  B-cell  lymphoma  and 
this overexpression is associated with increased invasion and metastasis  35. Dyskeratosis 
congeita 1 (DKC1) is a predominantly nucleolar protein that is essential for the formation of 
pseudo-uridine in RNA and the telomerase RNA subunit hTR 36, 37. Overexpression of DKC1 
has been observed in solid tumors, and the silencing of DKC1 can reduce telomerase activity 
and rRNA pseudouridylation 38. Zinc finger E-box binding homeobox 1 (ZEB1) is associated 
with adverse clinical presentation and clinical outcome in large B-cell lymphoma (LBCL) 39. 
It may very well be that the high ZEB1 levels are caused by the MYC-induced repression of 
miR-150. The poorer prognosis in of ZEB1 positive DLBCL may thus be consistent with the 
poorer prognosis observed for MYC positive B cell lymphoma.
MiR-26a/b induced a more than 50% decrease in GFP positive cells in 21 days. One 
of the validated miR-26a/b target genes, BAG-4 has been shown to bind to anti-apoptotic 
protein Bcl-2 40. Another validated target is PLAG1. PLAG1 is a transcription factor 41 and 
a oncogene first discovered in studies of pleomorphic adenomas of the salivary glands 42. 
Overexpression of PLAG1 was observed in CLL cells, compared to normal peripheral B cells 
43. This is not consistent with our findings that miR-26a levels are higher in CLL as compared 
to normal GC B-cells and BL. These differences are possibly caused by differences in control 
sample, being normal pheripheral B cells or BL. MiR-26a also targets oncogene EZH2 44 and 
EZH2 has been shown to induce MYC expression, which might represent another feedback 
loop 45. Van Kemenade et al (2001) 46 showed high expression of EZH2 in aggressive B cell 
lymphoma, in particular BL. This is consistent with our findings of low miR-26a expression 
levels in BL. The miR-26 target gene PTEN is a known tumor suppressor gene and its 
downregulation has been shown to play a role in MYC activation in T-ALL 47.  114
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Overexpression of miR-155 showed a marked increase in the percentage of GFP 
positive ST486 cells. MiR-155 has more than 100 validated target genes, including several 
genes that have been linked to the pathogenesis of B cell lymphoma. MiR-155 is a well 
know oncomiR that has been shown to have increased expression levels in various B-cell 
lymphoma such as Hodgkin lymphoma, primary mediastinal B-cell lymphoma and DLBCL 48. 
However, in BL miR-155 expression levels were strongly downregulated 49. Targeting of AID 
by miR-155 50, 51 may explain the pathogenetic relevance of this unexpected downregulation 
of miR-155 in BL. AID is involved in somatic hypermutation and class-switching of the 
immunoglobulin genes. Enhanced expression of AID results in the formation of chromosomal 
translocations involving the MYC locus  52. As MYC translocations are the hallmark of BL, 
it can be speculated that low levels of miR-155 are a prerequisite for the initiation phase 
of Burkitt lymphomagenesis, and that the tumor cells remain at that stage of maturation 
with ongoing AID expression. Another mechanism of enhanced AID expression might be 
achieved via induction of BCL6 which results in repression of miR-155 53. MiR-155 targets 
the proapoptotic gene Tp53INP1 in gastric MALT lymphoma 54. Via targeting HDAC4, miR-
155 indirectly results in enhanced levels of BCL6 and its target genes 55. Unpublished data 
by Slezak et al showed that inhibition of the protein coding isoform of TBRG1 phenocopies 
the miR-155 induced effects in ST486 cells, which indicates that this gene may play an 
important role in the observed miR-155 phenotype. These findings are consistent with the 
postulated role of TBRG1 as a growth inhibitory protein  56. Another target of miR-155 is 
Phosphatidylinositol, 3-kinase regulatory subunit alpha (PIK3R1) 57. PIK3R1 is required for 
normal functioning of PTEN. Loss of PTEN function leads to activation of AKT which in turn 
drives cell survival and proliferation 58, 59. 
In conclusion, we have shown that MYC repressed miRNAs miR-150 and miR-26a/b 
strongly inhibit cell growth whereas miR-155 overexpression results in a growth advantage 
for BL. As MYC regulates the expression of many protein coding genes and miRNA genes it 
is remarkable that the modulation of a single MYC regulated miRNAs has such a profound 
effect on cell growth.  MYC regulated miRNAs play a role in the high proliferative state of Burkitt lymphoma cells
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Supplementary Figure
Supplementary  figure  1.  Schematic  overview  of  the  viral  vectors  used  for  miRNA  and  sponge 
overexpression.  A.  Retroviral  miRNA  overexpression  construct.  PGK  =  phosphoglycerate  kinase 
promotor, miRNA(s) = miRNA gene, IRES = internal ribosome entry site, GFP = green fluorescent 
protein. B. Retroviral combi-sponge overexpression construct. Sponge = sponge with multiple binding 
sites (MBS) for multiple miRNAs, PGK = phosphoglycerate kinase promotor, IRES = internal ribosome 
entry site, GFP = green fluorescent protein. C. Schematic representation of the GFP competition assay. 
The GFP percentage was determined tri-weekly for three weeks. Depending on the change in GFP 
percentage the miRNA can be considered to have oncogenic activity, no effect or tumor suppressor 
activity.
Supplementary Table 1. Primer sequences used for cloning the miRNA stem-loop regions
miRNA Forward primer (5’-3’) Reverse primer (5’-3’)
miR-26a-1 catgctacctcgagcctgcccactgctgaccc ctcatgcagaattcctgtagtcctcagtcaccc
miR-26b gtgcgaagctcgagatacatgtggaatgtcagagg gttagcacgaattcgcacaggaaggagactggg
miR-29a gttggctagctcgaggggatgaatgtaattgtacagg gatggaattcgtgaaattcaacttagaaactgg
miR-29b-2 cctctctactcgagatgttgccttgtgcagccc ccacgtatgaattcctctactgtcacctctccc
miR-29-c ggtgctagctcgagttgggtgtcgattgtcatgg gttagcacgaattctcagttacagaagttagtaggg
miR-101 cttgctacctcgagccttctttttcttctgcctcc ctcacgatgaattcagaagcagaataactctccc
miR-142-3p gtagcagactcgaggtagaggaggcaagtctgg gtcacgatgaattcaggcctttcaggcatctgg
  Let-7a-1 cttgcacctcgagtgcatagattatgcatgtagcc ctcacgatgaattcaagaagcaaaaggtttcccc
miR-150 gttggctagctcgagcagtttctgcgactcaggg gatggaattcaacaggacaggacacacgg
miR-155 cttggctagctcgagtgtcactccagctttataacc catggaattcacagattgaaaaatgataaagcc
5’LTR 3’LTR GFP IR miRNA(s) PGK
No effect 
Oncogene activity 
Tumor supressor activity 
Retroviral 
infection
21 day
cell culture 
5’LTR 3’LTR GF IR puromyc PGK sponge
A
B
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Chapter 6
Summary and Discussion
Most non-Hodgkin lymphoma (NHL) subtypes are characterized by specific chromosomal 
aberrations and aberrant gene expression patterns, some of which have been shown to 
be particularly relevant to their pathogenesis. In the past decade research on microRNAs 
(miRNAs) has further contributed to the insight into the pathogenesis of NHL, but the picture 
is far from complete. MiRNAs are a group of regulatory small RNAs that belong to the non-
coding RNA family. MiRNAs can post-trancriptionally regulate the expression of their target 
genes, which include oncogenes and tumor suppressor genes, and as such contribute to 
tumorigenesis. Studies on miRNAs might therefore further improve our understanding of 
the molecular abnormalities that underlie the pathogenesis of lymphomas and cancer in 
general. 
This thesis focused on the role of miRNAs in the pathogenesis of lymphomas, 
in particular that of diffuse large B cell lymphoma (DLBCL, chapter 2 and 3) and Burkitt 
lymphoma (BL, chapter 3, 4 and 5). 
Patients with DLBCL have a great diversity in both clinical presentation and outcome. 
About 4% of DLBCL present at immune privileged (IP) extranodal sites such as the testis and 
the central nervous system (CNS). In spite of their low incidence, these lymphomas form 
a very specific subset of DLBCL with amongst others, a distinct pattern of dissemination, a 
distinct ABC type gene expression, very high levels of AID mediated mutations, and frequent 
loss of HLA class I and II expression. The aim of our study presented in chapter 2 was to 
identify miRNAs that are specifically expressed in testicular and CNS DLBCL. We examined 
the expression of 15 miRNAs known to play a role in B-cell pathogenesis in 50 cases of Ann 
Arbor stage I and II primary DLBCL. The DLBCLs consisted of testicular, CNS, other primary 
extranodal non-IP and nodal DLBCL. Our analysis revealed that miR-21 and miR-19b showed 
the highest expression levels in the total DLBCL group and also in each of the four subgroups. 
Previous studies have examined the miRNA profile between GCB and non GCB DLBCL but 
to date no clear consensus miRNA pattern that discriminates between these two DLBCL 
subtypes has been found 1. We found no significant differences between GCB and non-GCB 
DLBCL when we examined the combined IP, non-IP and nodal group and also not when we 
specifically focused on the nodal DLBCL subgroup. The lack of a consistent miRNA pattern 
discriminating between GCB and non-GCB may in part be related to the heterogeneous 
nature of the DLBCL group and the fact that most studies used different in- and exclusion 
criteria. 
By comparing testicular and CNS IP DLBCL to non-IP extranodal and nodal DLBCL 
we found that 2 of the 15 miRNAs showed significant differences. One of these miRNAs Summary and Discussion | Future Perspectives
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was miR-17, which showed a significant higher expression level in CNS DLBCL compared 
to testicular DLBCL and nodal DLBCL. These findings are in line with results published by 
Fischer et al. who identified miR-17 as one of the miRNAs differentially expressed when 
CNS DLBCL was compared to nodal DLBCL 2. In a recent study by Baraniskin et al 3 3 miRNAs, 
i.e. miR-19, miR-21 and miR-92, were identified as markers for primary CNS DLBCL. We 
also analyzed these miRNAs, but did not find significant differences. These differences 
between studies may be caused by different sample preparation, the use of a different 
housekeeping gene or the relative smaller sample size used in their study. MiR-17 and one 
of its seed family members, i.e. miR-20a, target transforming growth factor beta induced 
receptor type II (TGFBRII) and this results in reduced transforming growth factor-β (TGFβ) 
signaling 4. The second miRNA we identified was miR-127, which was significantly higher 
expressed in testicular DLBCL when compared to CNS and nodal DLBCL. A relevant miR-127 
target in relation to DLBCL biology is BCL6. Consistent with this, we observed an inverse 
correlation between BCL6 and miR-127 levels in DLBCL. Interestingly, miR-127 also targets 
B-lymphocyte-induced maturation protein 1 (BLIMP-1) and X-box binding protein 1 (XBP-1) 
5. MiR-127 has also been shown to be overexpressed in EBV positive BL compared to EBV 
negative BL and GC B-cells and to be differentially expressed during B-cell development 5. 
The differences in expression of miR-127 and miR-17 may reflect the different biological 
identities of testicular DLBCL and CNS DLBCL. 
In  chapter  3  we  investigated  the  expression  levels  of  the  primary  miR-17~92 
transcript, C13ORF25, and the expression pattern of the six mature miRNAs in 117 non-
Hodgkin lymphoma (NHL) cases, 21 NHL cell lines and three B-cell subsets. Within the 
normal B-cell subsets, a significantly higher C13ORF25 level was observed in naïve B cells 
compared to GC B cells. In the NHL cases and cell lines, BL consistently showed the highest 
C13ORF25 levels. Of the mature miRNAs, miR-92 levels were most abundant in the B cell 
subsets, all NHL cell lines and in the MCL, BL and CLL cases. In the DLBCL cases, the miR-19b 
levels were higher than the miR-92 levels. The high miR-19b expression levels observed in 
this series of DLBCL is consistent with the high expression levels observed in IP, non-IP and 
nodal DLBCL studied in chapter 2. Comparison of the miRNA levels between the NHL and 
their normal counterparts showed a consistent strong induction of miR-19b in all cases and 
cell lines of all four NHL subtypes. The induction of miR-19b is consistent with its known 
oncogenic role 6, 7. The marked increase of miR-19b is suggestive of an increased stability 
and/or increase in processing efficiency in B-cell NHL as compared to normal B cells. This 
is supported by a recent study of Ji et al 8 who also suggested that C13ORF25 miRNAs are 
affected by transcriptional mechanisms and varying processing efficiencies.126
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To gain a more complete insight into the role of miRNAs in B cell lymphoma we 
examined the miRNA expression profiles of four normal B cell subsets, MCL, FL, pediatric BL 
and CLL (Chapter four). Unsupervised clustering revealed two main clusters, i.e. one for the 
normal B cell subsets and one for the four lymphoma samples. In the normal B cell subsets 23 
differentially expressed miRNAs were identified, with GC B cells and plasma cells showing the 
most specific patterns. 73 miRNAs were differentially expressed between the four lymphoma 
subtypes. Remarkably, most of these miRNAs were specifically deregulated in BL. Within this 
study, BL wasis the only NHL subtype characterized by high MYC expression. Consistent with 
this, 39 of the 49 known MYC regulated miRNAs were differentially expressed between BL 
and the other NHL subtypes. The strong influence exerted by MYC on the miRNA expression 
profile in BL suggests that MYC regulates cellular processes directly at the transcriptional 
level of both protein coding genes and miRNAs and indirectly by the regulatory effects of the 
miRNAs. Interestingly, a study by Ji et al 8 showed that the promotor region of C13ORF25 is 
not only bound by MYC but also by inhibitory members of the MYC family suggesting a more 
intricate relationship between MYC and miR-17~92.  Several NHL carry an amplification 
of 13q31 encompassing the primary miR-17~92 transcripts (C13ORF25). We studied the 
influence of this amplification on the expression of miRNA members of this cluster. High 
expression of miR-17~92 cluster members was strongly associated with 13q31 amplification 
in our series of B cell NHL. Our data are consistent with the results published by Schiffman 
et al 9, who found miR-17 expression to be correlated with 13q31 gain in pediatric BL and 
Tagawa et al 10 who demonstrated a higher expression of the miR-17~92 cluster in t(8;14) 
positive BL and DLBCL cases with 13q31 amplification as compared to t(8;14) cases without 
this amplification. Also, Rinaldi et al 11 showed 13q31amplification and higher expression of 
miR-17~92 in human mantle cell lymphoma.
In chapter 5 we investigated the role of eleven MYC regulated miRNAs that were 
differentially expressed between BL and CLL as based on the expression profiling studies 
performed in chapter 4. The levels of ten of these miRNAs were low in the MYC-high BL 
cases, whereas the level of one miRNA was high in BL compared to the levels in MYC-low CLL 
samples. Differences in expression were validated on the same set as used for the original 
microarray study and confirmed on an independent set of BL and CLL cases. Overexpression 
of the MYC repressed miRNAs in BL revealed for six miRNAs a 50% or more decrease in the 
percentage of miRNA over expressing cells (based on co-expression of GFP) in a period of 
18 days. This indicated that most MYC repressed miRNAs strongly influence the growth of 
BL cells. One MYC repressed miRNA, i.e. miR-155, showed a more than 50% increase in 
GFP+ cells upon overexpression indicating a strong growth advantage. It is remarkable that 
of the high number of known MYC regulated genes and miRNAs, overexpression of a single Summary and Discussion | Future Perspectives
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MYC regulated miRNA can already have a strong influence on cell growth of a BL cell line. 
Recent studies 12, 13 have shown that MYC is most likely not associated with repression of 
gene transcription but rather acts as an amplifier of active gene transcription. Genes that 
were previously described as being repressed by MYC are most likely genes that are not 
induced by MYC or induced less than average compared to other actively transcribed genes. 
This may also be the case for the previously identified MYC repressed miRNAs, including 
those that have been studied by us. Although these miRNAs may not be actively repressed 
by MYC, low expression is clearly beneficial for the high proliferative state of BL cells. 
In conclusion, we identified two miRNAs that characterize the testicular and CNS 
DLBCL  cases.  We  further  showed  marked  differences  in  the  expression  pattern  of  the 
oncogenic miRNA cluster, miR-17~92 with miR-92 being the most abundant miRNA in most 
cases, and miR-19b being the most significantly induced miRNA as compared to their normal 
counterparts. We further established specific miRNA expression profiles in different NHL 
subtypes and showed that the profile of BL is strongly defined by MYC. Finally, we identified 
seven MYC regulated miRNAs that have a remarkably strong impact on growth of BL cells.
Future Perspectives
Since the initial discovery of miRNAs 10 years ago it has become clear that miRNAs play an 
important role in the regulation of gene expression. In fact, miRNAs are predicted to regulate 
the expression of up to 60% of all protein coding genes. MiRNAs also play an important role 
in most human diseases including cancer. Many miRNAs are located in genomic regions that 
are either amplified or deleted in human cancers and miRNA expression studies have shown 
that most human cancers exhibit aberrant miRNA expression. In this thesis we focus on one 
type of cancer in particular, namely B-cell NHL.
Analysis of miRNA expression for the identification of differences between specific 
types of NHL is a topic with great clinical potential. Various miRNAs have already been 
identified as individual markers or as part of a specific profile for certain B-cell NHL, such as 
DLBCL, CLL, MCL and FL and also in differentiating BL from DLBCL 14. In the most recent WHO 
classification of tumors of hematopoietic and lymphoid tissues 15, the largest category of 
DLBCL is DLBCL not otherwise specified (NOS). This includes all cases of DLBCL-NOS) that do 
not belong to a specific subtype or other category of DLBCL as defined the WHO 2007. It is 
in this category of DLBCL where that miRNA expression profiling may play an important role 
by further defining various subgroups in the future. The importance of miRNAs as diagnostic 
biomarkers may lay in the more subtle context of the differential diagnosis of uncertain 
histopathological cases. It is possible that miRNAs could play a role in the identification of so 
called grey zone lymphoma such as B-cell lymphoma with features intermediate between 128
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diffuse large B-cell lymphoma and Burkitt lymphoma and B-cell lymphoma with features 
intermediate between primary mediastinal large B-cell lymphoma (PMBL) and classical 
Hodgkin  lymphoma  (HL).  As  grey  zone  lymphomas  have  an  aggressive  clinical  course 
and poor outcome, identification of miRNAs that can clearly distinguish these grey zone 
lymphomas would be clinically advantageous. To date, no clear miRNAs markers have been 
found for grey zone lymphoma and as such this offers an interesting direction for practical 
application of miRNA expression studies. 
To further define miRNA expression profiles in DLBCL we examined 14 DLBCL cases 
comprised of nodal, IP and one case of extranodal DLBCL NOS. MYC status was determined 
using FISH and GCB/non-GCB status was defined using the algorithm described by Hans et 
al 16. Unsupervised hierarchical clustering of the 350 miRNAs that were expressed revealed 
a clear clustering of two groups of patients (Fig 1A). Localization, MYC status or GCB/non-
GCB status showed no correlation with this clustering pattern. A student t-test performed 
between the cases that grouped in the two clusters revealed 75 significantly differentially 
expressed miRNAs (Fig 1B). We subsequently examined a separate set of cases previously 
published by Montes-Moreno et al 1. A similar miRNA expression pattern was observed using 
a subset of the 75 miRNAs that were present on their array. Although further analysis of our 
experimental data still needs to be performed, these initial results point towards possible 
miRNA defined subgroups of DLBCL that to our knowledge has not yet been described. 
Recent technical advances in sequencing technology of mRNA has greatly enhanced 
the detection of alternative splice variants, alternative poly-A usage and sequence variants 
of transcripts. Similarly, small RNA sequencing technology has facilitated identification of 
novel miRNAs, sequence variants introduced by ADAR editing and changes in prevalence of 
isoforms. Combined with techniques such as Ago2-RIP-Chip and variants thereof, can now 
be used to reliably identify miRNA target sequences in a genome-wide high throughput 
procedure. In a recent study by Deng et al (2011) 17, a specific regulation of a selection of 
transcript isoforms by miRNAs has been observed. Similarly, we also observed a specific 
regulation of the protein coding isoforms of TBRG1 by miR-155. This indicates that miRNA-
target gene regulation is a complex process regulated by multiple factors. 
The expansion of our knowledge on the miRNA expression pattern in B-cell NHL 
has opened novel pathways for clinical applications. Specific miRNA expression patterns 
have been used as a method for predicting therapy response, detection of minimal residual 
disease and survival. Detection of such miRNAs in plasma, serum and CNS fluid offers a 
unique opportunity for minimally invasive monitoring methods. Four miRNAs, i.e. miR-15a, 
miR-16-1, miR-29c and miR-155, were downregulated, and miR-34a was  upregulated in 
serum of DLBCL patients  18. In a study by Ohyashiki et al  19 miR-92a plasma levels were Summary and Discussion | Future Perspectives
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found to be downregulated in DLBCL, FL and T cell NHL compared to healthy subjects. In 
chapter three we found miR-19b as the most abundant miRNA in DLBCL cases and we 
also observed relatively high levels of miR-92a. Differences in results may be caused by 
patient selection. In our study we used only Ann Arbor stage I and II primary DLBCLs. In 
the study by Ohyashiki et al, plasma levels of miR-92a were measured in DLBCL patients in 
complete remission, relapse patients and also patients with Ann Arbor stage 3 and stage 4 
DLBCL. Moreover, normalization procedures especially for circulating miRNAs need to be 
further optimized. Ohyashiki normalized all miRNA levels to the most abundant miRNA in 
their samples, although they observed great variation in the absolute levels of this miRNA. 
Additional  studies  are  required  to  clearly  establish  these  putative  differences  between 
tissue and plasma.
Figure. 1. Expression profiles of DLBCL cases  A. Unsupervised clustering of 14 DLBCL cases revealed 
two distinct clusters A and B. No correlation was found with parameters such as location and MYC 
status. B. A Mann Whitney test revealed 74 significantly differentially expressed miRNAs between 
cluster A and B. 21 of the 74 miRNAs were available in a seperate dataset published by Montes 
Moreno containing 29 DLBCL cases. Supervised clustering of the same 29 cases using the same order 
of miRNAs as depicted in our cases showed a similar but less distinct expression pattern.
 ﾠ
Cluster A  Cluster B 
A 
Montes Moreno et al., 2011  Our cases  B 130
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The critical involvement of specific miRNAs in different types of cancer has sparked 
the interest in miRNAs as a therapeutic option. MiRNAs target multiple genes and offer the 
possibility to impact tumor phenotype by either repressing individual oncogenes but also 
allow for the possibility of targeting a specific subset of genes and as such affecting selected 
pathways. Approaches to utilize miRNAs for therapy broadly fall into two categories: 1); 
downregulation  of  oncogenic  miRNAs  using  antagomiRs,  antisense  oligonucleotides, 
sponges or locked nucleic acid (LNA) constructs and 2); replacement of repressed tumor 
suppressor miRNAs. A promising miRNA that has been utilized for therapeutic purposes 
is miR-122. Suppression of miR-122 in chimpanzees chronically infected with hepatitis C 
virus (HCV) using locked nucleic acid (LNA) modified oligos complementary to miR-122 
caused long-lasting suppression of HCV virema 20. LNA-modified antisense oligonucleotide 
miravirsen are currently in phase 2 clinical trials for treatment of hepatitis C virus (HCV) 
infection.
MiR-10b has been shown to promote metastasis and invasion by targeting HOXD1 
and TIAM1 21, 22 in breast cancer. Molyneaux et al 23 showed that treatment with miR-10b 
antagomiRs reduced metastasis of breast tumors to the lungs in mice. As many miRNAs 
are downregulated in tumors, restoring tumor suppressive miRNAs is another potential 
therapeutic possibility. In our study we identified 6 MYC regulated miRNAs, i.e. miR-150, 
miR-26a, miR-26b, miR-29a, miR-29b and miR-101 that strongly inhibit the growth of BL 
cells. A study by Kota et al 24 showed that therapeutic delivery of miR-26a suppresses 
tumorigenesis, reduces cancer cell proliferation and induces tumor cell specific apoptosis 
in a murine liver cancer model. Specific delivery of miR-26a and the five other miRNAs we 
identified in our study could provide therapeutic options for BL. 
In this thesis we focus on the expression and role of miRNA in NHL. MiRNAs belong 
to the large group of noncoding RNAs (ncRNAs) which are generally divided by their size. 
Long ncRNAs (lncRNAs) are > 200 bp and consist of long intergenic noncoding (linc) RNAs, 
pseudogenes, ribosomal genes and antisense RNAs. Non-protein coding RNAs < 200nt are 
called small ncRNAs and include small nuclear and nucleolar RNAs, ribosomal RNAs, transfer 
RNAs, Piwi interacting RNAs and miRNAs. As more knowledge has been gained in recent 
years about these noncoding RNAs their role in lymphogenesis is becoming apparent 25. For 
example lncRNA HOTAIR has been shown to be upregulated in primary breast tumours and 
metastases. Another lncRNA, Malat1 has been shown to be important for colorectal cancer 
invasiveness and is upregulated in cancers such as neuroblastoma and osteosarcoma. 
Future  studies  on  the  various  species  of  ncRNA  in  lymphoma  will  reveal  how 
widespread their involvement in lymphomagenesis is.Summary and Discussion | Future Perspectives
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Nederlandse samenvatting
Micro  (mi)RNAs  zijn  korte,  22  nucleotiden  (nt)  lange,  regulatoire  RNA  moleculen  die 
onderdeel uitmaken van de familie van niet coderend RNAs. MiRNAs kunnen gericht de 
expressie van bepaalde genen beïnvloeden, onder andere van tumorsuppressor genen en 
oncogenen. De laatste 10 jaar heeft onderzoek op het gebied van microRNAs (miRNAs) 
bijgedragen aan een beter inzicht in de pathogenese en het gedrag van diverse vormen van 
kanker waaronder B-cel lymfomen en leukemieën. 
Dit  proefschrift  richt  zich  op  de  rol  van  miRNAs  in  de  pathogenese  van  B-cel 
lymfomen, specifiek die van het diffuus grootcellig B-cel lymfoom (DLBCL, hoofdstuk 2 en 3) 
en van het Burkitt lymfoom (BL, hoofdstuk 3, 4 en 5).
Patiënten met DLBCL tonen een grote diversiteit aan klinische symptomen en in de 
uiteindelijke uitkomst van de ziekte. Het doel van de in hoofdstuk 2 beschreven studie was 
om te onderzoeken of er in deze heterogene ziekte groepen met een verschillend miRNA 
expressie patroon zijn te vinden. Hiervoor hebben we ons beperkt tot de expressie van 15 
miRNAs. Deze miRNAs waren geselecteerd op basis van hun mogelijke rol in de pathogenese 
van B-cel lymfomen. De 50 DLBCL waren geselecteerd op basis van duidelijke verschillen in 
primaire lokalisatie: ze bestonden uit conventionele nodale DLBCL, maar ook uit primaire 
extranodale DLBCL. Om onduidelijkheid over localisatie te voorkomen betrof het in alle 
gevallen een DLBCL met zeer beperkte uitzaaiing, dat wil zeggen Ann Arbor stadium I en 
II. Onze analyse liet zien dat alle DLBCL een zeer hoge expressie hadden van miR-21 en 
miR-19. DLBCL kunnen op basis van RNA en eiwit expressie onderscheiden worden in van 
kiemcentrum origine (“germinal centre B-cell” / GCB) of van geactiveerde B cel origine 
(“activated B-cell” / ABC, ook wel non-GCB genoemd). Voor deze twee subsets zijn in de 
literatuur verschillende miRNA profielen beschreven, echter een duidelijke consensus is tot 
op heden niet gevonden. In onze studie vonden wij geen significante verschillen tussen GCB 
en ABC DLBCL. Wij vonden ook geen verschil toen wij gericht keken binnen alleen de nodale 
DLBCL subgroep. Het ontbreken van een eenduidig discriminerend miRNA expressiepatroon 
tussen GCB en ABC DLBCL is mogelijk het gevolg van de heterogene aard van DLBCL en het 
feit dat de meeste studies verschillende inclusie- en exclusiecriteria hanteren en dat een 
onderscheid tussen nodaal en extra-nodaal onvoldoende is. 
Ongeveer 4% van DLBCL presenteert zich in de testis en het centrale zenuwstelsel 
(CNS). Dit zijn twee extranodale lokalisaties waar normaal gesproken geen immunologische 
afweer voorkomt. Deze specifieke subgroep wordt de “immune privileged” of IP-DLBCL 
genoemd. Deze IP-DLBCL worden gekenmerkt door een specifiek patroon van uitzaaiing, 
een ABC genexpressie patroon, hoge frequentie van AID-gemedieerde mutaties en frequent 136
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voorkomen van verlies van HLA klasse I en II expressie. Door testis en CNS IP-DLBCL te 
vergelijken met andere non-IP extranodale en nodale DLBCL vonden wij miRNAs met een 
significant verschillend expressie niveau. Een van deze miRNAs is miR-17, deze liet een 
hoge expressie zien in CNS DLBCL in vergelijking tot testis DLBCL. Onze bevindingen komen 
overeen met eerder gepubliceerde resultaten waarbij miR-17 geïdentificeerd werd als een 
van de miRNAs die verschillend tot expressie komen wanneer CNS DLBCL wordt vergeleken 
met nodal DLBCL. In een recente studie werden miR-19, miR-21 en miR-92 geïdentificeerd 
als kenmerkend voor primair CNS DLBCL. Wij hebben deze drie miRNAs ook geanalyseerd 
maar vonden geen significante verschillen. De verschillen tussen de studies zijn mogelijk 
veroorzaakt door verschillen in de methode, het gebruik van andere controle huishoudgenen 
of het relatief klein aantal lymfomen dat werd bestudeerd. De tweede miRNA die wij in onze 
studie hebben geïdentificeerd is miR-127. Deze miRNA komt significant hoger tot expressie 
in testis DLBCL in vergelijking tot CNS DLBCL en nodale DLBCL. Eén van de relevante miR-
127 target genen is BCL6. BCL6 speelt een belangrijke rol in de biologie van DLBCL. In   
overeenstemming hiermee vonden wij een omgekeerde correlatie tussen BCL6 en miR-127 
expressie in DLBCL. De verschillen in expressie van zowel miR-17 als miR-127 in testis DLBCL 
en CNS DLBCL reflecteren dus zeer waarschijnlijk belangrijke stappen in de normale B cel 
ontwikkeling.
In hoofdstuk 3 hebben we de expressie van het primaire miR-17~92 transcript 
en de mature miRNAs in B-cel lymfomen onderzocht. Dit oncogene miRNA cluster bevat 
zogenaamde  “stem-loop” structuren (de DNA basis structuur waar een miRNA van kan 
worden afgelezen) voor 6 miRNAs, miR-17, miR-18a, miR-19a, miR-20a, miR-19b en miR-
92.  Het primaire transcript heeft twee iso-vormen. Bij de lange isovorm bevinden de stem-
loop structuren zich in het exon en bij de andere iso-vorm in een intron. Opvallend is dat 
de expressie van de individuele mature miRNAs sterk kan verschillen terwijl ze alle zes 
afkomstig zijn van hetzelfde primaire transcript. Om dit nader te onderzoeken hebben wij de 
hoeveelheid van de zes miRNAs bepaald in drie B-cel maturatie stadia, 117 B-cel non-Hodgkin 
lymfomen en in 21 B-cel lymfoom cellijnen. De 4 maturatie stadia waren naïeve B-cellen, 
kiemcentrum B-cellen, geheugen B-cellen en plasmacellen, allemaal selectief geïsoleerd uit 
hyperplastische  tonsillen. De expressie van miR-92 was in normale B-cel subsets en drie 
B-cel lymfoom subtypen 10 tot 100x hoger dan de vijf andere miRNAs. Alleen in DLBCL was 
de expressie van miR-19 hoger dan de expressie van miR-92. In vergelijking met de normale 
voorloper cellen zagen we een sterk verhoogde expressie van met name miR-19b in alle 
lymfoom subtypen. Voor miR-92 en de andere vier miRNAs werden echter geen verhoogde 
expressieniveaus gevonden ten opzichte van de normale B-cellen. De sterke inductie van 
miR-19b komt overeen met de oncogene effecten in muismodellen. Onze data suggereren Nederlandse samenvatting
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dat er op individueel miRNA niveau een sterke regulatie is van de hoeveelheid mature 
miRNAs. Mogelijk wordt dit bereikt door verschillen in de processing efficiency van de zes 
precursor miRNAs en/of door verschillen in de stabiliteit van de mature miRNAs.
Om  een  completer  inzicht  in  de  rol  van  miRNAs  in  B-cel  lymfomen  te  krijgen 
hebben wij in hoofdstuk 4 de miRNA expressieprofielen onderzocht van de vier normale 
B-cel maturatie stadia (zie hoofdstiuk 3) en vier maligne lymfomen die ook een duidelijk 
maturatie  stadium  vertegenwoordigen:    mantelcel  lymfoom  (MCL;  reflecteert  naïeve  B 
cellen), folliculair lymfoom (FL; reflecteert kiemcentrum B-cellen), Burkitt lymfoom (BL; 
reflecteert ook kiemcentrum B-cellen) en chronische lymfatische leukemie (CLL; reflecteert 
geheugen B cellen). Ongesuperviseerd clusteren van de miRNA expressie data toonde twee 
hoofdgroepen aan, namelijk één voor de normale B-cel maturatie stadia en één voor de 
vier lymfoom subtypen. In de normale B-cel maturatie stadia vonden wij 23 differentieel tot 
expressie komende miRNAs waarbij de GC B-cellen en plasmacellen de meest uitgesproken 
patronen toonden. 73 miRNAs kwamen differentieel tot expressie tussen de vier lymfoom 
subtypes. Opvallend was het feit dat de meeste van deze miRNAs specifiek gedereguleerd zijn 
in BL. Binnen het kader van deze studie was BL het enige NHL subtype dat gekarakteriseerd 
wordt door hoge MYC expressie. In overeenstemming hiermee vonden wij dat 39 van 
de 49 bekende MYC gereguleerde miRNAs differentieel tot expressie komen tussen BL 
en de andere lymfoom subtypes. De sterke invloed die wordt uitgeoefend door MYC op 
het miRNA expressieprofiel in BL suggereert dat MYC de genexpressie op verschillende 
manieren reguleert, namelijk direct op het niveau van transcriptie van eiwit coderende 
genen en indirect door middel van regulatoire effecten van miRNAs. Andere studies hebben 
aangetoond dat de promotor van miR-17~92 niet alleen gebonden wordt door MYC maar 
ook door inhibitoire leden van de MYC familie. Dit suggereert dat er een complexe relatie 
bestaat tussen MYC en miR-17~92. Meerdere lymfoom subtypen bevatten een amplificatie 
van het 13q31 gebied dat ook de genomisch sequenties  van het mir-17~92 gen bevat. Wij 
hebben de invloed van deze amplificatie op expressie van het primaire miRNA transcript en 
de mature miRNA clusterleden bestudeerd. Hoge expressie van het miR-17~92 cluster en de 
zes mature miRNAs was sterk geassocieerd met de aanwezigheid van een 13q31 amplificatie. 
Onze data komen overeen met de resultaten van andere studies waarin miR-17 expressie 
gecorreleerd is met 13q31 amplificatie in pediatrische BL en waarin een hogere expressie 
van miR-17~92 in BL en DLBCL geassocieerd is met amplificatie van 13q31. Daarnaast is een 
hogere miR-17~92 expressie ook aangetoond in MCL met een 13q31 amplificatie.
In hoofdstuk 5 hebben wij de rol van 11 MYC gereguleerde miRNAs onderzocht 
die differentieel tot expressie komen tussen BL en CLL, gebaseerd op de expressiestudies 
van hoofdstuk 4. De expressieniveaus van tien MYC onderdrukte miRNAs waren verlaagd 138
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in BL (allen met een hoge MYC expressie) en het MYC geïnduceerde miRNA toonde hoge 
expressie in BL in vergelijking met de CLL (allen met een lage MYC expressie). Verschillen 
in expressieniveaus werden gevalideerd op dezelfde set van lymfomen als gebruikt in de 
oorspronkelijke miRNA expressiestudie in hoofdstuk 4 en in een onafhankelijke set van 
CLL en BL. Om de functie van deze miRNAs te bestuderen hebben we de 10 miRNAs die 
verlaagd waren in BL cases tot overexpressie gebracht in een BL cellijn. Overexpressie van 
de MYC onderdrukte miRNAs in BL toonde voor zes van de miRNAs een afname in groei 
van tenminste 50% gedurende een periode van 18 dagen. Dit geeft aan dat deze zes MYC 
onderdrukte miRNAs een sterke invloed uitoefenen op de groei van BL cellen. Een van 
de MYC onderdrukte miRNAs, miR-155, toonde een meer dan 50% toename in groei bij 
overexpressie, hetgeen indicatief is voor een toegenomen proliferatie. Het is opmerkelijk 
dat overexpressie van slechts één enkel MYC gereguleerd miRNA al zo’n sterke invloed kan 
hebben op  de proliferatie van BL cellen, omdat  MYC een zeer groot aantal eiwit coderende 
en  miRNAs  reguleert.  Recente  studies  hebben  aangetoond  dat  MYC  waarschijnlijk  niet 
zozeer geassocieerd is met het onderdrukken van gentranscriptie maar meer een algemene 
versterker is van de transcriptie van die genen die in een bepaalde cel op dat moment al 
aan staan. Genen die voorheen als MYC onderdrukte genen werden beschreven zijn dan 
hoogstwaarschijnlijk genen die niet of in mindere mate door MYC worden geïnduceerd in 
vergelijking tot andere actief getranscribeerde genen. Mogelijk is dit ook het geval voor MYC 
onderdrukte miRNAs en dus ook de miRNAs beschreven in deze studie. Ondanks dat deze 
miRNAs mogelijkerwijs niet actief door MYC worden onderdrukt is lage expressie van deze 
miRNAs klaarblijkelijk van belang voor de proliferatie van BL cellen.
Samenvattend hebben wij in dit proefschrift twee miRNAs geïdentificeerd die CNS 
en testis DLBCL karakteriseren. Wij laten ook zien dat er duidelijke verschillen zijn in de 
expressiepatronen van de zes mature miRNAs afkomstig van het oncogene miRNA cluster, 
miR-17~92, met miR-92 als meest voorkomend miRNA in het merendeel van de gevallen en 
miR-19b als het meest significant geïnduceerde miRNA in vergelijking met normale B-cellen. 
Tevens hebben wij aangetoond dat er specifieke miRNA expressieprofielen in verschillende 
lymfoom subtypes zijn en dat het expressieprofiel van BL sterk beïnvloed wordt door MYC. 
Als laatste hebben wij zeven MYC gereguleerde miRNAs geïdentificeerd die een zeer sterke 
invloed uitoefenen op de proliferatie van BL cellen.139
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